Clinical, Molecular and Imaging Study in Neuromuscular Disorders in Developmental age: contribution to the genotype-phenotype correlation by ASTREA, GUJA
UNIVERSITÀ DI PISA
PhD School in Neuroscience and Endocrinometabolic Science
PhD Programme: Basic and Developmental Neuroscience 
Head: Prof. Giovanni Cioni
Clinical, Molecular and Imaging Study in 
Neuromuscular Disorders in Developmental 
age: contribution to the genotype-phenotype 
correlation
Tutor
Prof. Giovanni Cioni
Candidate
Dr.ssa Guja Astrea
XXV CYCLE (2010-2012)
SSD MED 39
2
 Ad Angelina, 
detta Evangelina 
e a tutte le stelle 
che sono nel cielo
….
e sulla terra
3
4
Contents
Acknowledgements.......................................................9
Abbreviations...............................................................11
Overview of the Thesis..........................................13
Chapter 1: Introduction
1 Neuromuscular Disease in Children: diagnostic 
challenges....................................................................20
1.1. Distal hereditary motor neuropathies....................23
1.2. Congenital Myopathies.........................................26
1.3. Congenital Muscular Dystrophies.........................29
2 Muscle MRI: a useful tool for differential diagnosis of 
Muscular Disorders......................................................32
Chapter 2: Clinical and genetic studies
1 Clinical  and genetic  characterization of  distal  spinal 
muscular atroph  y  ..........................................................36
1.1. TRPV4 mutations in children with congenital distal 
spinal muscular atrophy...............................................37
Introduction
Materials and methods
Results
Discussion
References
5
1.2.  A  novel  mutation  in  DYNC1H1  bridges  the  gap 
between  motor  neuropathy  and  neuronal  migration  
defect...........................................................................51
Introduction
Case report
Discussion
References
2 Identification of a new form of Neutral Lipid storage 
Disease........................................................................56
2.1.  Subclinical  myopathy in  a child  with  neutral  lipid  
storage  disease  and  mutations  in  the  PNPLA2  
gene.............................................................................57
Introduction
Case report
Results and Discussion
References
3  Difficult  orient  ation   approach  in  CMD-LGMD:  the  
genetic point of view............................. .......................68
3.1. Genetic breakdown in a large cohort of Congenital  
Muscular  Dystrophies:  update  of  the  Mutation  
Spectrum......................................................................69 
Introduction
Patients and methods
Results
Discussion
Conclusion
References
6
Chapter 3: Muscle MRI studies
1 Muscle MRI: what we learn by pattern recognition 
analysis......................................................................100
1.1. Muscle MRI in TRPV4-related  neuromuscular 
disorders....................................................................101
Introduction
Patients and methods
Results and Discussion
References
1.2.  Discovery of a novel  RYR1 mutation through the 
use of muscle MRI.....................................................105
Introduction
Case report
Discussion
References
2 Expanding the use of muscle MRI: from overall 
pattern to pattern within muscle.................................114
2.1. Can muscle  MRI help distinguish myopathic from 
neurogenic genetic causes of distal weakness?........114
Introduction
Methods
Image analysis
Results
Discussion
References
7
Chapter 4: The Brain involvement 
1  The brain involvement in DMD patients  ..................132 
1.1. Duchenne Muscular Dystrophy and Developmental  
Dyslexia:  comparison  of  reading  and 
neuropsychological profile.........................................132
Introduction
Patients and methods
Statistical analyses
Results
Discussion
References
Conclusions and future directions 
Publications and scientific communications
8
Acknowledgements
This PhD has represented for me a unique opportunity 
for professional and personal growth.
I  consider  myself  extremely  lucky  that  i've  got  the 
chance to rely on the mentorship, constant support and 
friendship of many people who have enriched, inspired 
and filled with sense my experience.
I feel towards them deeply grateful.
First of all, I would like to thank Prof. Giovanni Cioni for 
his  mentorship  over  almost  a  decade and for  having 
always encouraged and trusted in me. I feel  truthfully 
grateful to him for his guidance and for having always 
respected  my  interests.  He  also  gave  me  the 
opportunity to develop a part of my PhD in London, an 
experience of priceless value. 
My deep gratefulness also goes to prof. F. Muntoni who 
welcomed  me  in  his  research  groups,  supported  the 
development of the muscle MRI studies.
I could never forget all the UK friends and their families: 
Mariacristina,  Irene,  Silvia,  Sophelia,  Valeria, 
Francesco, Stephany, Adnan, Ruth, for their friendship, 
generosity  and  support,  that  made  my  experience 
down-under warm and unforgettable.
Roberta,  thank  you  so  much  for  having  been  an 
excellent  mentor  and  a  sincere  friend,  for  having 
generously shared your knowledge and having always 
helped me when I needed it. You taught me how to be 
proactive and to overcome the sense of insecurity I felt 
when trying to put together our projects.
Filippo, I am deeply grateful to you for your mentorship, 
all the practical and moral support you generously gave 
me,  for  having  taught  me  so  much  about  research 
9
methodology and for always sustaining me in pursuing 
my own ideas.
Thanks  to  Dott.ssa  Chiara  Fiorillo,  Dott.  C.  Bruno, 
Dott.ssa S.Perazza and S.Frosini. I learned many things 
from them, and among those I learned the importance 
of multidisciplinary work in research.
I  am  very  grateful  to  Chiara  Pecini  for  the  essential 
contribution  to  the  development  of  the  study 
neuropsycological  protocol  in  DMD  and  for  her 
friendships and her support.
Thanks  to  the  staff  of  the  Molecular  Medicine  and 
Neurogenetic Laboratory of IRCCS Fondazione Stella
Maris its welcome, appreciation and help to ride over 
difficulties.
Last but not least, I’d like to thank all the children and 
their families i have met during my studies, both in UK 
and Italy. They made me appreciate how our everyday 
work  as  physicians  relies  on  the  generosity  of  the 
families  who  accepted  in  the  years  to  give  their 
contribution to research.
My  profound  gratefulness  goes  to  my  family  and 
especially my sister, for supporting and helping me with 
the  English  translation  and  my  nephews  that  always 
inspire me.
But  the  biggest  acknowledgment  of  all  goes  to  my 
husband Sergio. I thank you Sergio for your patience, 
your  tireless  and  your  constant  encouragement  and 
your love.
  
10
Abbreviations
MRI       Magnetic Resonance Imaging 
dHMN   distal Hereditary Motor Neuropathies 
dSMA   distal Spinal Muscular Atrophies 
CMT      Charcot Marie Tooth 
CM        Congenital Myopathies 
CMD     Congenital Muscular Dystrophy 
LGMD   Limb-girdle muscle disease
DMD     Duchenne Muscular Dystrophy
11
12
Overview of the Thesis
    
     
13
Inherited  neuromuscular  disorders  represent  a 
heterogeneous group of human diseases with a large 
clinical  and  genetics  overlap  and  affecting  almost 
invariably  muscle  strength  and  size.  Oftentimes, 
clinicians  face  a  brain  teasing  mixture  of  clinical  and 
laboratory findings and combine them like in a puzzle to 
offer  a  certain  and  complete  diagnosis.  Thus,  this 
category  of  human  disorders  represent  a  diagnostic 
challenge in clinical neurology for which a high level of 
medical, molecular and imaging knowledge is needed to 
reach a final diagnosis and offer patients an adequate 
rehabilitation  management  or  appropriate  prospective 
follow up and therapies. 
My interest in neuromuscular disorders goes back to the 
latest years of my residency in Pediatric Neurology in 
IRCCS  Stella  Maris  and  the  initial  work  on  the 
characterisation of a novel pattern of muscle MRI in a 
rare  progressive  myopathy  with  characteristic 
pathological  findings  (Astrea  et  al.,  Neuromuscular 
Disorders 2009).  At that time, using clinical  data and 
features at muscle MRI we contributed to discover the 
gene  causing  the  reducing  body  myopathy,  helping 
clinicians in recognising this rare muscular condition. 
The experience gathering during residency years taught 
me how to use a “hand lens” to focus not only on clinical 
symptom  and  sign  in  children  with  neuromuscular 
disorders  but  also  to  integrate  genetics  and  imaging 
approaches, to develop a true curiosity for the molecular 
basis  of  muscular  dystrophies  and  to  use  a 
multidisciplinary approach when facing a young patient.
During  my  PhD  course  I  also  had  the  possibility  to 
attend  one  of  the  most  important  European 
Neuromuscular  Centre,  the  Dubowitz  Neuromuscular 
14
Centre  (London,  UK)  under  the  direct  supervision  of 
prof. F. Muntoni and the Neuromuscular Department of 
the Catholic University in Rome (with the supervision of 
prof. E. Mercuri). Particularly, I could spend six months 
in London for a research fellowship training to improve 
my knowledge in muscle MRI examination and grading 
system. The specific training was crucial in detecting a 
well  known pattern  of  muscle  MRI  associated  with  a 
congenital  myopathy  in  two sisters whose clinical  and 
immunoistological findings were misleading and unable 
per se to pinpoint the right diagnosis. The draft of the 
manuscript  describing  our  findings  in  that  family  has 
been submitted to the Neuromuscular Disorders journal. 
Furthermore, this professional training led me to a more 
exhaustive  analysis  of  muscles  involvement  at  MRI. 
With the aim of evaluating the sensitivity and specificity 
of a visual inspection of muscle imaging scans so as to 
identify clues able to differentiate distal neurogenic from 
distal  myopathic  diseases,  I  spent  research  time 
focusing  on  the  identification  of  discrete  alterations 
within  muscle  fibers  because  a  simple  visual  pattern 
recognition  could  not  be  sufficient  in  neurogenic 
diseases. The presence of «islands» preserving muscle 
bulks  in  a  background  of  fatty  transformations  was 
serendipitously  —yet  consistently  —  noticed  and  it 
could represent a “red flag” for neurogenic conditions, 
regardless of the genetic defect. 
The pattern of involvement within muscles, that is not 
something normally captured by the standard approach 
adopting the so termed “Mercuri grading” or reviewing 
pattern analyses reported in the literature, seems to be 
the most intriguing and useful diagnostic marker of late 
changes in distal neurogenic clinical conditions.
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Finally the collaboration with Dubowitz Neuromuscular 
Centre offered me the possibility to study a large series 
of  cases  presenting  a  clinical  diagnosis  of  CMD 
(congenital  muscular  dystrophy)  in  a  second  tier 
molecular  genetic  laboratory  in  UK,  as  well  as  the 
chance  to  draw  interesting  observations  in 
genotype-phenotype  correlations  and  relative 
prevalence  of  CMD  and  allelic  limb-girdle  muscular 
dystrophies in large population. 
Equally important during the PhD research years were 
the  opportunities  to  collaborate  closely  with  the 
Molecular  Medicine  and  Neurogenetic  Laboratory  of 
IRCCS Fondazione  Stella  Maris  (in  collaboration  with 
Drs. F.M. Santorelli  and C. Fiorillo). Thanks to such a 
collaboration, we could discover and characterise a new 
form of lower limb spinal muscular atrophy (SMA) in two 
patients and the related mutations in the  TRPV4 gene 
(Neurogenetics, 2012),  and  to  integrate  the  clinical, 
genetics  and  imaging  findings  in  an  original  article 
focused  on  the  description  of  the  pattern  on  muscle 
involvement at myoimaging (Astrea et al,  Neurology, 
2012).  The  still-growing  number  of  new  genetic 
aetiology  for  lower  limb neuromuscular  disorders was 
an  important  opportunity  for  embedding  clinical 
management  and  pattern  recognition  on  muscle  MRI 
giving  aid  to  the  definition  of  pathogenicity  of  a  new 
mutation  and further  clinical  correlation.  An additional 
manuscript  will  be  shortly  finalized  on  the  clinical 
genetics and imaging characterization of a new form of 
SMA with lower limb predominance (under submission). 
Using  the  same  approach,  it  was  also  possible  to 
describe a presintomatic form of lipidic myopathy due to 
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neutral lipid storage disorder (Biochem Biophys Res 
Commun, 2013).
Finally,  to  obtain  and  even  wider  comprehension  of 
neuromuscular  disorders,  I  have  participated  in  the 
study  design,  obtaining  of  data  and  interpretation  of 
results in an original  study with the goal to verify the 
presence  and  characteristics  of  literacy  deficits  in 
children with Duchenne Muscular Dystrophy (DMD) and 
the  analyses  of  their  neuropsychological  profiles 
associated  with  reading  abilities.  This  was  done 
comparing  DMD patients  with  similarly  aged  dyslexic 
children. Such a study explains how a multi-component 
cognitive  deficit  may  contribute  to  specific  literacy 
difficulties  in  DMD  with  rapid  access  to  lexicon  and 
phonological  processing being the core deficits in our 
subjects.  As  a  practical  consequence,  our  study 
suggested that a careful evaluation of specific reading 
abilities should be part of periodic clinical evaluations of 
DMD children in  pre-school  years and prompt correct 
rehabilitation of those components that appear deficient. 
The manuscript describing the study and the results has 
recently been submitted to PlosONE journal.
To summarize,  my doctoral  thesis  has a wide scope, 
resulting  from  a  research  effort  put  on  better 
characterization of  genotype-phenotype correlations in 
different forms of neuromuscular disorders, highlighting 
the usefulness of muscle MRI in differential  diagnosis 
and  to  expand  its  use  for  a  better  depiction  of 
pathogenic mechanisms in inherited muscle diseases. 
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Chapter 1
Introduction
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1 Neuromuscular Disease in Children: 
diagnostic challenges
Neuromuscular  diseases  are  disorders  caused  by  an 
abnormality  of  any  component  of  the  lower  motor 
neuron  system:  anterior  horn  cell,  peripheral  nerve, 
neuromuscular junction, or muscle (Figure 1).
Figure 1 Anatomic Breakdown of Disorders of the Lower 
Motor Neuron.
The given condition can be either genetic or acquired. 
From the practical point of view, the anterior horn cell 
has  got  two  separate  disorders.  Spinal  muscular 
atrophy is  the genetically  determined condition  of  the 
anterior horn cell, whereas poliomyelitis is acquired. The 
genetic disorders of the peripheral nerve are named as 
hereditary sensory motor neuropaties,  which could be 
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seen  with  mendelian  and  mitochondrial  DNA 
inheritance. These are either axonal or demyelinating. 
The acquired demyelinating neuropathy is autoimmune 
based. If the latter condition is axonal, then toxic causes 
should be investigated. Myastenias overall encompass 
about 2% of neuromuscular disorders in childhood with 
majority  being  the  congenital  forms.  Anatomically, 
congenital  myasthenic  syndromes  are  classified 
according  to  the  site  of  the  abnormality  being 
pre-synaptic,  synaptic  or  post-synaptic.  Slow  channel 
syndrome is seen less frequently than the other forms. 
The  disorders  of  the  primary  muscle  tissue  can  be 
divided  into  muscular  dystrophies,  congenital 
myopathies,  metabolic  conditions  and  acquired 
diseases.  Juvenile  dermatomyositis,  iatrogenic 
myopathies  and  endocrine  myopathies  are  typically 
acquired, where as the remaining are hereditary. 
These group of disorders are diagnostically challenging 
as many of them also pose other systemic findings. One 
example would the commonly seen mental retardation 
in  Duchenne  muscular  dystrophy.  A  detailed  family 
history  is  mandatory.  Physical  stigmata  such  as 
localized atrophy or hypertrophy must be noted along 
with the functional  evaluation,  although the overlap of 
clinical  phenotype  among  different  categories,  which 
includes  common  and  not  specific  symptoms,  makes 
the diagnosis tricky. 
Recently  the standard diagnostic  pathway has largely 
moved  on  from  muscle  biopsy  analysis  to  genetics, 
even though mutation analysis remains complex owing 
to  the  large  numbers  of  genes  involved  and  the 
challenges  of  the  latest  generation  of  sequencing 
techniques,  which are still  not  yet  in  routine  use and 
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which produce vast amounts of data that are impossible 
to analyse without guidance from the phenotype, as the 
large numbers of variants found in every patient require 
interpretation  of  clinical  relevance  to  discover  the 
pathogenic  change.  Muscle  imaging,  especially 
magnetic  resonance  imaging,  is  exceptionally  helpful 
and depict often the most important tool in this task.
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1.1. Distal hereditary motor neuropathies
The distal hereditary motor neuropathies (dHMN) are a 
phenotypically and genetically heterogeneous group of 
diseases  affecting  lower-motor-neurons  and 
characterised by slowly symmetrical  progressive distal 
limb weakness (1). They are also termed distal spinal 
muscular  atrophies  (dSMA).  There  is  frequently  an 
overlap  of  clinical  findings  in  dHMN  and  other 
neurogenic  conditions,  like  hereditary  motor  and 
sensory  neuropathy  or  proximal  spinal  muscular 
atrophy. Many of dHMN are, in fact, allelic with subtypes 
of  Charcot  Marie  Tooth  2  (CMT2)  disease  with  the 
principle  distinction  being  mild  to  moderate  sensory 
nerve involvement in CMT2 (1).
The cardinal feature of dHMN is usually a very slowly 
progressive length-dependent condition often starting in 
the  first  two  decades;  onset  in  the  third  decade  is, 
however, not uncommon. Poor performance in sports at 
school  and  insidious  progression  are  useful  clues, 
whereas a short, de novo history in middle age should 
prompt  a  search  for  an  acquired  aetiology.  Bulbar 
involvement, other than the recurrent laryngeal nerve, is 
rare in dHMN. The examination,  as expected,  usually 
confirms distal wasting and weakness with reduced or 
absent  reflexes,  and  neurophysiology  highlighted 
reduced  motor  amplitude  potentials  associated  with 
EMG  changes  suggesting  chronic  distal  predominant 
denervation (2). 
Using this approach, a significant proportion of patients 
classified  as dHMN will  be ‘sporadic’  with no obvious 
family history and in this case a dominant mutation is 
assumed. Once the hereditary nature of the disease is 
established,  delineation  of  clinical  and 
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neurophysiological phenotype is the most efficient way 
to  approach  genetic  tests.  Neurophysiological  studies 
are  useful  to  differentiate  CMT2  from  dHMN; 
electromyography  is  not  only  used  to  confirm 
denervation  but  also  in  differentiating  dHMN  from  a 
distal  myopathy.  However,  the  yield  remains  low,  as 
more than 80% of patients with dHMN have mutations 
in  undiscovered  genes;  early  detection  of  these 
condition is so not so easy and more gene have to be 
test  before perform a correct  diagnosis,  with negative 
implication  in  genetic  counselling  (2).  The  causative 
genes have implicated proteins with diverse functions 
such as protein misfolding (HSPB1,  HSPB8,  BSCL2), 
RNA  metabolism  (IGHMBP2,  SETX,  GARS),  axonal 
transport  (HSPB1,  DYNC1H1,  DCTN1)  and 
cation-channel  dysfunction  (ATP7A and  TRPV4)  in 
motor-nerve  disease  (2).  At  present,  we  are  able  to 
recognise  seven  categories  of  dHMN  and  other  four 
forms  with  associated  specific  features.  These 
conditions  are  inherited  in  autosomal  dominant  or 
recessive pattern and only one form is X-linked; some 
genes  are  associated  with  sensitive  involvement  and 
are linked to CMT disease (2). Type I and II are typical 
distal motor neuropathies beginning in the lower limbs 
and  presenting  in  either  childhood  or  adulthood, 
respectively.  Both  can  be  due  to  mutations  either 
HSPB1 or HSPB8, demonstrating that these phenotypic 
categories  are  genetically  heterogeneous.  If  sensory 
involvement is present, the disease is termed CMT2F if 
it  is  due  to  mutations  in  HSPB1 and  CMT2L  if  the 
mutations reside in HSPB8. dHMN with pyramidal signs 
can be due to mutations in BSCL2 and SETX and they 
have also been linked to three separate loci 9p21.1p12 
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(HMN-Jerash),  7q34q36  and  4q34.3q35.2.  BSCL2 is 
also allelic to spastic paraplegia type 17 (SPG17, Silver 
syndrome). Type V is characterised by upper-limb onset 
and can be due to mutations in BSCL2 or GARS: if it is 
due to a mutation in  GARS and there is also sensory 
involvement, it is termed CMT2D. Type VII is associated 
with vocal cord paralysis and can be due to mutation in 
DCTN1,  TRPV4 or  in  an  yet  unidentified  gene  on 
chromosome 2q14.6.  dHMN  types  III,  IV  and  VI  are 
autosomal recessive distal motor neuropathies. Type III 
and  IV  have  been  linked  to  the  same  loci  and  are 
chronic forms of dHMN. They are differentiated by the 
presence  of  diaphragmatic  palsy  in  type  IV.  Type  VI 
occurs  in  infancy  and  it  is  characterised  by  distal 
weakness and respiratory failure. It is due to mutations 
in the gene IGHMBP2 (1-2). 
The  overlap  between  clinical  and  genetic  findings 
makes  difficult  the  differential  diagnosis  in  this 
heterogeneous group of diseases. 
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1.2. Congenital Myopathies
The  congenital  myopathies  (CM)  are  a  distinct  and 
markedly  heterogeneous  group  of  muscle  disorders 
which  are  clustered  into  subtypes  based  on  the 
predominant pathological features revealed on muscle 
biopsy.
The clinical presentation includes congenital hypotonia, 
delayed  motor  milestones,  feeding  difficulties,  muscle 
weakness,  facial  muscle  involvement,  and 
ophtalmoplegia,  although  certain  features  are  more 
frequently associated with distinctive conditions. Serum 
creatine kinase values are generally normal or slightly 
raised  and  the  course  of  the  disease  is  essentially 
static.  In  addition  to  congenital  onset,  there  is 
heterogeneity in the onset as well as the clinical course 
of the disease, even among affected members from the 
same  family.  Together  with  progressive  or  slowly 
progressive weakness there are patients  with a more 
severe course, and still others with late onset or almost 
asymptomatic presentations (1).
In  the  last  decade,  several  new  genes  and  proteins 
responsible  for  individual  forms  of  CM  have  been 
identified  and  the  classification  has  expanded 
considerably.  Moreover  some  advances  have  also 
started to explain the pathological mechanisms of these 
disorders, providing the basis for therapeutic strategies 
(2, 3).
More specifically it has been found that:
1)  mutations  in  the same gene can produce different 
pathological  features,  affecting  different  pathogenetic 
pathways  within  muscle  sarcomere.  For  example, 
mutations in  alpha−skeletal  actin  can cause nemaline 
myopathy,  myopathy  with  cores  and  congenital  fibre 
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type  disproportion  (CFTD).  Mutations  in 
alpha−tropomyosinSLOW can  result  in  both  nemaline 
myopathy  and  CFTD.  Mutations  in  beta−tropomyosin 
can result in nemaline myopathy and cap disease, and 
mutations in selenoprotein N can result in multiminicore 
disease and CFTD, as well as dystrophic pathology.
In  addition,  the  same  mutation  can  cause  different 
pathological  features  also  in  members  of  the  same 
family  or  in  the  same  individuals  at  different  ages, 
suggesting  that  modifyng  genes  or  environmental 
factors  may  influence  the pathological  appearance  of 
the muscle.
2)  the  same clinical−morphological  phenotype can be 
associated with mutations in different genes. Nemaline 
myopathy,  for  example,  is  currently  associated  with 
seven known genetic loci. Mutations in several different 
genes can cause core pathology and CFTD. 
Therefore, although clinical symptoms together with the 
muscle  biopsy  and  the  imaging  of  the  muscle  group 
degeneration pattern are able to define an increasing 
number of specific conditions, the genetic confirmation 
of the protein defect is essential for definitive diagnosis 
and reasonable taxonomy.
As  such,  a  new  classification  based  on  the 
morphological−genetic  correlation  has  been  proposed 
(2, 3):
−Myopathies with protein accumulation
−Myopathies with cores
−Myopathies with central nuclei
−Myopathies with fibre size variation
However,  most  of  the  disorders  are  genetically 
heterogeneous, firm genotype−phenotype relationships 
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remain  as yet  unclear,  and further  genes have to be 
found.
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1.3. Congenital Muscular Dystrophies
Classically  the  term  congenital  muscular  dystrophy 
(CMD)  includes  a  group  of  genetically,  clinically  and 
biochemically  distinct  entities  sharing  clinical  and 
pathological  features  such  as  early  presentation  of 
weakness  and  hypotonia  and  dystrophic  features  on 
muscle biopsy. In the last few years the identification of 
several  new  genes  responsible  for  different  forms  of 
CMD has not only expanded the spectrum of the known 
forms of CMD but has produced exciting progresses in 
the  understanding  of  the  mechanisms underlying  this 
group of disorders.
The incidence and prevalence of CMD in populations is 
not  sufficiently  known.  Part  of  this  uncertainty  stems 
from the limited diagnostic means available in the early 
1990s  at  the  time  when  patients  were  initially 
ascertained for some of the larger surveys. The range of 
point prevalence that can be gleaned from these studies 
ranges from 0.68 to 2.5 per 100,000, which could still be 
an  underestimate  (1-4).  The  relative  frequency  of 
individual  types  does  vary  in  different  populations 
depending on the respective genetic  background.  For 
instance, in Japan the most commonly diagnosed form 
is  Fukuyama  CMD  caused  by  a  founder  mutation  in 
fukutin,  followed  by  collagen  VI  deficient  CMD  (5), 
whereas  fukutin  mutations  are  very  rare  in  other 
populations (4).
Most of these studies were performed before the recent 
advances  and  identification  of  new  genes  that  have 
changed the scenario of CMD.
To date over 20 genes responsible for CMD forms have 
been identified. These forms can be classified into five 
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main  groups  according  to  clinical,  pathological  and 
genetic data:
1. CMD due to mutations in genes encoding structural 
proteins of the basal membrane or extracellular matrix 
of the skeletal muscle fibers. These include forms due 
to mutations in the genes encoding collagen VI, laminin 
alpha  2  (merosin)  and  integrin  alpha-7  and  integrin 
alpha-9.
2. CMD due to mutations in genes encoding putative or 
demonstrated  glycosyltransferases,  which  affect  the 
glycosylation  of  alpha-dystroglycan.  These  include 
FCMD, MEB and WWS, and other forms with normal 
brain MRI, with and without mental retardation.
3. CMD with rigidity of the spine, due to mutations in the 
SEPN1  gene,  which  encodes  selenoprotein  1,  an 
endoplasmic reticulum protein of unknown function.
4.  CMD  due  to  abnormalities  of  nuclear  envelope 
proteins (LMNA and nesprin),
5.  CMD  with  mitochondrial  structural  abnormalities 
(CMDmt).
This classification only includes forms of CMD in which 
the primary genetic defect has been identified, but there 
are several  other forms with distinctive phenotypes in 
which the underlying defect has not yet been identified.
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2  Muscle  MRI:  a  useful  tool  for  differential 
diagnosis of muscular disorders
In  the  past  few  years,  muscle  Magnetic  Resonance 
Imaging  (MRI)  has  become  an  important  tool  in  the 
detection  and  characterization  of  pathological 
alterations of   skeletal  muscle that  cause changes in 
muscle signal intensity, becoming an additional tool for 
diagnosing  inherited  neuromuscular  disorders  (1). 
Following the description of a short muscle MRI protocol 
to be used in young patients, MRI has become suitable 
also for paediatric population (2). 
The use of this technique has mainly been devoted to 
identifying  patterns  of  muscle  involvement  and  has 
revealed  patterns  of  selective  involvement  that  in  a 
number of cases are fairly disease-specific. Exactly why 
certain muscles are spared from pathology despite the 
fact  that  the  proteins  involved  are  ubiquitously 
expressed  is  a  question  that  has  still  not  been 
adequately  answered.  Nevertheless,  the 
characterization of these patterns has helped to improve 
the diagnostic work-up of patients with neuromuscular 
disease,  guided  genetic  testing  and  helped  in  the 
differential  diagnosis  of  muscle  disorders  with 
overlapping of clinical features (1); the identification of a 
typical  muscle  MRI  pattern  aids  also  the  often 
challenging  task  of  assigning  pathogenicity  to  those 
novel genetic variants with uncertain significance. 
More  recently,  the  new  challenge  has  become  the 
possibility to use muscle MRI not only for diagnosis but 
as an outcome measure, trying to quantify muscle size, 
signs  of  inflammation,  fatty  replacement  or,  using  fat 
suppression, other causes of abnormal signal (3). Other 
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studies  have  also  explored  whether  the  correlation 
between muscle histology and MRI changes could aid 
to better understand the alteration arising in the muscle 
during the course of the disorder and to acquire more 
specific information useful for clinical trial (4). 
Although  muscle  MRI  can  provides  an  excellent 
non-invasive visualization of anatomical structures, such 
as nerves, MRI studies have been focused on a limited 
series  of  CMT  patients  including  cases  with  CMT1A 
duplication  (5)  or  CMT2  associated  with  DNM2 
mutations (CMT2/DNM2) (6) or CMT2A associated with 
MFN2 mutations (CMT2A/MFN2)  (7).  Too few studies 
have been carried out on evaluation of specific pattern 
in dSMA (8) or on identification of different markers able 
to differentiate myopathic forms from neurogenic ones. 
The knowledge in this field are rapidly  improving and 
new information are likely  to be achieved using more 
advanced MRI techniques. 
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 Chapter 2
Clinical and genetic studies
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1 Clinical and genetic characterization of distal 
spinal muscular atrophy 
Inherited  forms  of  slowly  progressive  neurogenic 
weakness and wasting may be labeled, on the basis of 
nerve conduction involvement, as distal spinal muscular 
atrophy  (dSMA),  when  nerve  conduction  function  is 
spared,  distal  hereditary  motor  neuropathy  (dHMN), 
when  the  involvement  is  only  motor,  or  axonal 
Charcot-Marie-Tooth  (CMT2),  when both sensory  and 
motor nerves are affected. However, in the “exome era”, 
the  rapidly  growing  list  of  mutated  genes 
(http://neuromuscular.wustl.edu/),  high  levels  of  allelic 
and  genetic  heterogeneity,  and  overlapping  of 
conditions are tending to limit the usefulness of precise 
clinical-nosographic labels.
The  recent  identification  of  mutations  in  the  gene 
encoding  transient  receptor  potential  vanilloid  4 
(TRPV4)  in  distal  spinal  muscular  atrophy  (dSMA) 
prompted us to screen for mutations a small group of 
children with a compatible phenotype.
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1.1  TRPV4  mutations  in  children  with  
congenital distal spinal muscular atrophy
by  Chiara  Fiorillo,  Francesca  Moro,  Guja  Astrea,  Claudia 
Nesti,  Giacomo  Brisca,  Zoltan  Balint,  Andrea  Olchewsky, 
Christian Guelly,  Michaela  Auer-Grumbach,  Roberta Battini, 
Filippo M. Santorelli and Claudio Bruno 
manuscript  published  in  Neurogenetics  2012; 
13(3):195-203
Introduction
Congenital distal spinal muscular atrophy (dSMA) (MIM 
600175) is a lower motor neuron disease with prenatal 
onset,  autosomal  dominant  inheritance,  and  variable 
clinical  severity  ranging  from  muscle  weakness 
predominantly affecting the lower limbs to more severe 
neurogenic  muscle  weakness  and  arthrogryposis.  A 
form of  dSMA is associated with mutations in transient 
receptor  potential  vanilloid  4  (TRPV4)  —  the  gene 
encoding  a  calcium-permeable  ion  channel  of  the 
vanilloid  subfamily  —  that  operate  through  a 
loss-of-function mechanism (1). TRPV4 also determines 
two  allelic  disorders,  scapuloperoneal  SMA  (SPSMA, 
MIM  181405)  and  hereditary  motor  and  sensory 
neuropathy  2C (HMSN2C,  MIM 606071)  (2,  3,  4,  5). 
Although  also  dominantly  transmitted  and  involving 
preferentially the distal legs, they show unique features: 
SPSMA presents also scapular weakness and atrophy, 
whereas  HMSN2C  combines  motor  and  sensory 
involvement,  diaphragm  and  intercostal  muscle 
weakness,  and  hearing  loss.  However,  overlap 
phenotypes  and  intrafamilial  variability  between  and 
within kindred harboring the same mutation have been 
described (1-4). On top of this, dominant mutations in 
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TRPV4 also  cause  clinical  conditions  affecting  the 
bones — without signs of primary muscle weakness — 
ranging  from  mild  brachyolmia  and 
spondylomethaphyseal  dysplasia  to  lethal  neonatal 
metatropic  dysplasia  (6).  Type  of  the  mutations  and 
location  within  the  protein  domains  are  believed  to 
account for this wide clinical heterogeneity. 
Reviewing our pooled databases of dSMA patients, we 
screened six apparently sporadic patients for variants in 
TRPV4 and detected two mutations, including a novel 
variant.
Material and methods 
Three  girls  and  three  boys  (age  range  2-21  years, 
median  age  at  onset  2±2,  median  age  at  latest 
examination  15.5±7)  were  selected  because  their 
clinical  characteristics  satisfied  the  clinical  and 
electrophysiological criteria of dSMA. In particular, there 
were  neurogenic  muscle  weakness  and  atrophy  in 
lower (in all patients) and upper limb (in two), congenital 
arthrogryposis (in three cases), scoliosis (in four), and 
vocal cord paralysis (in a single child).
EMG  and  muscle  biopsy  examinations  confirmed  a 
neurogenic  damage  of  muscle  and  nerve  conduction 
studies  were  normal  in  all.  Respiratory  and  cardiac 
functions were normal. No patient displayed involved of 
CNS nor sensation  defect (Table 1).  Mutations in the 
SMN1 gene had already been ruled out.
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Table 1 
Clinical characteristics of patients with distal spinal muscular 
atrophy (dSMA) screened for mutations in TRPV4 
Patient Age Molecular 
analysis
Phenotype Clinical Features
1 12 yrs c.290 C>G 
(p.P97R)
dSMA and 
vocal cord 
paralysis
Congenital 
arthrogryposis. Vocal 
cord paralysis. Severe 
scoliosis. 
2 2.5 
yrs
c.694 C>T 
(p.R232C)
dSMA and 
Platispondi
lia
Congenital 
arthrogryposis. Shoulder 
amyotrophy. Hoarse cry. 
Platispondilia, short 
phalanges, dysmorphic 
femoral heads. 
3 19yrs wild-type dSMA Pes cavus. Independent 
walking
4 10yrs wild-type dSMA Distal leg weakness. 
Scoliosis. Independent 
walking
5 21yrs wild-type Scapulo-p
eroneal 
SMA
Congenital 
arthrogryposis. Shoulder 
amyotrophy.  
Ophtalmoplegia. 
6 19 yrs wild-type dSMA Pes cavus. Bladder 
urgency. Pyramidal 
signs.
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The coding exons and flanking introns of  TRPV4 were 
amplified by PCR  and bidirectionally sequenced using 
the BigDye v3.1 chemistry (Applied Biosystems Foster 
City,  CA),  on  an  ABI3500  DNA  analyzer. 
Chromatograms were analyzed and aligned against the 
reference  sequence  using  SeqScape  v2.6  software 
(Applied  Biosystems).  For  the  description  of  the 
mutations we used the latest conventions of the Human 
Genome  Variation  Society  nomenclature.  New 
variations  were  systematically  evaluated  in  silico to 
predict  their  effects  on  protein  function  (Polyphen 
analysis,  genetics.bwh.harvard.edu/pph/;  ESEfinder, 
www.rulai.cshl.edu/cgi-bin/tools/ESE/esefinder.cgi; 
www.fruitfly.org/seq_tools/splice.html).  Multiple 
alignment  with  TRPV4 orthologs  used  ClustalW 
(www.ebi.ac.uk/clustalw)  to  evaluate  the  degree  of 
conservation of missense variants.
Immunofluorescence  analysis  of  skin  and  muscle 
sections and fibroblasts was carried out using standard 
protocols.  Briefly,  serial  7-µm  thick  sections  of  the 
patients’  skin  and  skeletal  muscle  biopsies  were 
obtained  from  isopentan  frozen  samples.  Human 
fibroblasts were obtained from patient skin biopsy and 
grown in DMEM medium supplemented with 10% foetal 
bovine  serum  and  4.5  g/L  glucose.  Tissue  sections 
were pre-incubated with PBS+4%BSA for 10 minutes. 
Cells were fixed for 20 min in 4% paraformaldehyde in 
PBS, permeabilized with 0.1% Triton X-100 in PBS for 
15 min, then blocked for 1 hour in 10% FBS. Sections 
and cells were then incubated overnight at 4°C with a 
rabbit  polyclonal  anti-TRPV4  antibody  (1:100; 
Sigma-Aldrich, St. Louis, MO). diluted 1:1000 . The day 
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after  sections  and  cells  were  incubated  with  a 
fluorescein  isothiocyanate  (FITC)  labeled  goat 
anti-rabbit IgG Alexa Fluor 555 (Cell Signaling-Millipore, 
Billerica,  MA)  diluted  1:1000  for  1  hr  at  room 
temperature.  Nuclear  counterstained  was  performed 
using DAPI (Sigma-Aldrich, St. Louis, MO). Coverslips 
were mounted in mounting medium and visualized with 
fluorescence  microscope  Axio  Imager  M2(Carl  Zeiss, 
Oberkochen,  Germany).  No labeling  was observed in 
control  experiments  in  which  primary  antibody  was 
omitted.
Cloning  TRPV4_  wt  and  mutant  TRPV4_P97R 
constructs  in  expression  vectors,  heterologous 
expression in HeLa cells, measurement of intracellular 
calcium  concentration  (Ca2+i),  and  patch-clamp 
recordings were performed as previously described (1). 
Values were determined as means ± s.e.m. of number 
of  cells.  Intergroup  differences  for  Ca2+ imaging  and 
electrophysiology were assessed by a factorial analysis 
of variance using Fisher’s least-significant-difference as 
post hoc analysis. Statistical significance was set at p < 
0.05.
Results
In two children we identified mutations in TRPV4. Case 
1 is  a 11-years-old  girl  born by C-section  for  podalic 
breech. At birth, clubfoot and congenital hip dysplasia 
were evident, together with marked floppiness prevalent 
in lower limbs. There was also a bone fracture in the left 
femur. The patient was never able to stand up and walk 
without support. Her cognitive development was normal 
as  well  as  facial  and  upper  limb  muscles.  Sensation 
was never affected during a 9-year follow-up.  At age 5 
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years, the patient developed scoliosis whereas hoarse 
voice manifested at age 7. Paralysis of vocal cords was 
documented  by  video-endoscopy  of  upper  respiratory 
tract.  Neurophysiological  studies  documented  muscle 
denervation  on  EMG  with  polyphasic  potentials  and 
fibrillation  at  rest  whereas  sensory  and  motor 
conduction  velocities  were  normal.  Serum  creatine 
kinase  (CK)  levels  were  mildly  elevated  (221  U/L, 
normal <170 U/L). A skeletal muscle biopsy confirmed a 
neurogenic damage of muscle, showing hypertrophy of 
type  1  fibers  and  type  grouping  in  a  severely 
substituted/atrophic  muscle.  Spine  and  pelvis  X-ray 
images  documented  marked  thoraco-lumbar  scoliosis 
and  right  hip  dysplasia.  The  latest  neurological 
examination showed a bright young girl  confined to a 
manual wheelchair. She daily used a static stander with 
ischial support and wore a brace for scoliosis awaiting 
spine  surgery.   Lower  limbs  were  plegic  with  ankle, 
knee and hip contractures. Upper limbs appeared to be 
spared,  though  there  was  mild  weakness  in  the 
shoulder  girdle.  Deep  tendon  reflexes  were  absent. 
Cranial  nerves were unaffected but  the patient  spoke 
with a feeble and hoarse voice which worsened during 
minimal  exercise.  Laringeal  stridor  and  suprasternal 
retraction  were  occasionally  reported  during  more 
intense physical activity. Basal pulmonary function test 
showed nearly normal forced vital capacity (92%) and 
only a mild reduction of forced respiratory volume and 
peak expiratory flow (88% and 83%).
Case  2  is  a  2.5-year-old  boy born  at  39 weeks with 
bilateral  talipes and fractures of  right  clavicle  and left 
femur.  At  3  months  he  underwent  surgery  for  partial 
correction of foot deformation. The patient was able to 
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control  his head and could sit  without  support but he 
was never able to stand nor to walk. Gastrostomy was 
performed for severe gastroesophageal reflux at age 2 
years.  The  latest  neurological  examination  when  he 
was age 2.5 years showed severe involvement of lower 
limbs  with  complete  paralysis  and  moderate  atrophy. 
Only  distal  movement  of  toes  were  possible.  Initial 
knees retraction were present. The child could not raise 
his legs from bed and sat with a kyphotic posture. There 
was minimal shoulder weakness and bilateral tremor of 
hands. Deep tendon reflexes were reduced in all limbs. 
Cognition appeared to be normal; the boy was alert and 
smiling.  Full  range of  ocular  movement was possible. 
Crying  sounded  hoarse.  EMG  study  revealed  severe 
neurogenic  damage.  Nerve  conduction  studies,  EEG 
and brain and spine MRI studies were all  normal. CK 
was only mildly elevated (211 U/L, normal <170 U/L). A 
first  muscle biopsy at  age 12 months showed diffuse 
fatty replacement whereas a second biopsy at age 18 
months detected variability  of  fibre size with selective 
atrophy  of  type  2  fibres,  consistent  with  denervation. 
X-rays  imaging  documented  vertebral  abnormalities 
consistent  with  platispondilia,  short  and  stubby 
phalanges and dismorphic features of the femoral head.
By  direct  gene  sequencing,  we  identified  a  novel 
heterozygous c.290C>G variant in exon 2 of TRPV4 in 
case  1.  The  mutation  replaces  arginine  for  a  highly 
conserved  proline  at  residue  97  (p.P97R)  in  the 
cytosolic  N-terminus  of  human  TRPV4.  The  mutation 
was not  detected in  200 control  chromosomes and it 
was absent in genomic DNA from the healthy parents 
and  a  younger  brother.  In  case  2,  we  detected  an 
already reported c.694 C>T (p.R232C) in exon 4. This 
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mutation has been described in nine patients from three 
families,  and  associated  with  dSMA  and  vocal  cord 
paralysis in one family, dSMA and SPSMA in another 
kindred, and a HMSN2C clinical phenotype in the third 
family (4).
None of the remaining cases presented disease-related 
variants in TRPV4.
In  muscle  sections  from case 1,  we observed a faint 
and  diffuse  TRPV4  immunoreactivity  alike  control 
muscles. In skin sections from both patients, there was 
a strong staining in keratinocyte layer, endothelium and 
nerve  endings  as  expected  (7)  without  significant 
differences  between  patient  and  control.  No  relevant 
differences  of  expression  or  signal  localization  were 
detected between patients and controls in cultured skin 
fibroblasts.
To  evaluate  the  possible  functional  consequences  of 
the  novel  p.P97R  mutation,  we  expressed 
heterologously  both  mutant  and  wild-type  alleles  in 
HeLa cells. This system was preferred because HeLa 
miss detectable levels  of  the endogenous protein (1). 
Having  confirmed genuine  human  TRPV4 expression 
(1),  we  found  that  basal  calcium  levels  did  not 
significantly  differ  among  transfected  cells  whereas 
TRPV4_P97R  had  a  significantly  lower  response  to 
intracellular  calcium  increase  when  challenged  with 
hypo-osmotic  solution  (p<0.001)  (Figure  1).  Also,  the 
mutant  channels  yielded  significantly  smaller  currents 
(90% reduction) in patch-clamp studies when subjected 
to  a  hypo-osmotic  challenge  with  reduction  of 
extracellular osmolarity from 320 to 200 mOsm (Figure 
2) (p < 0.001).
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Figure 1 
Intracellular  calcium  changes  of  TRPV4-transfected  HeLa 
cells. (A) There was no difference in the basal calcium level of 
the  transfected  cell.  (B)  The  hypoosmotic  solution–induced 
calcium  response  was  significantly  reduced  in  the  mutant 
compared  to  wild-type.  (C)  Original  traces  show  calcium 
response  during  hypoosmotic  challenge  in  HeLa  cells 
transfected with wild-type or mutant TRPV4 channels (dashed 
line,  wild-type  hTRPV4;  continuos  line,  R-mut).  Control 
(dotted line) indicates a mock-transfected cell. (*** p<0.001, 
nexp = 7,  ncells = 37 for the wildtype,  ncells  = 35 for  the 
mutant). wt,  wildtype construct;  R-mut, construct presenting 
the p.P97R variant.
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Figure 2
Effect of substitutions on TRPV4 activation by hypo-osmotic 
swelling.  (A)  Effect  of  hypo-osmotic  challenge on wild-type 
hTRPV4  or  mutant  p.P97R  -transfected  HeLa  cells  in 
response to a ramp protocol. (B) Pooled data from the same 
series as shown in  A.  Average basal inward and outward 
currents at −100 mV and +100 mV of HeLa cells expressing 
hTRPV4 and mutants p.P97R (n ≥ 4). ** indicates significant 
differences compared to cells expressing hTRPV4 (p<0.01). 
Basal  values  are  shown  by  white  bars.The  values  of  the 
hypo-osmotic  challenge  are  indicated  by  gray  bars. 
Mock-transfected cells were used as a control
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Discussion
Upon screening of  TRPV4 in a small  group of dSMA 
children,  we  identified  a  child  bearing  a  reported 
p.R232C mutation in the ankyrin repeat domain (ARD)
— a region thought to be important for oligomerization 
and proper trafficking to the plasma membrane (7) — 
and a novel variant in the N-terminus of the protein. The 
pathogenicity  of  the  new p.P97R is  sustained  by  the 
following considerations: i) the mutation arose de novo 
in  the  family  and  it  was  not  found  in  a  large  set  of 
control chromosomes; ii) it possibly interferes with the 
nearby proline-rich region (PRD), though to be involved 
in mechanosensation and interaction with other proteins 
(8);  iii)  when  expressed  in  mutant  HeLa  cells,  the 
p.P97R causes a statistically significant loss of function 
mechanism when  challenged  by  hyposmotic  solution. 
Conversely,  there  was  no  abnormal  expression  or 
mislocalization  of  the  mutant  protein  when  tested  in 
patient’s  tissues  suggesting  that proline  97  might  be 
relevant for correct response to different stimuli.
The present report adds to the genetic heterogeneity of 
TRPV4-pathies  but  has  also  relevance  in  terms  of 
genotype-phenotype  correlations.  It  is  of  interest  that 
case 2 in this work, who carried a mutation in the ARD 
domain,  also  presented  a  well  defined  primary  bone 
pathology documented by X-ray scans. This finding is 
seldom seen in children with distal muscular weakness 
and  it  is  rather  associated  with  dominant  mutations 
outside  the  ARD  domain  (9).  Contrariwise,  case  1, 
bearing  a  mutation  outside  the  ARD  domain, 
manifested  unspecific  skeletal  abnormalities  such  as 
congenital  fracture,  hip  dysplasia,  scoliosis  and  fixed 
joint contractures without sustaining images. Thus, the 
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first  conclusion  that  can be drawn is  that  a clear-cut 
molecular correlation between type of mutation, position 
of  the  variant  in  protein  domains  and  the  resulting 
phenotype in TRPV4-pathies can be hardly proposed. It 
seems  more  reasonable  to  hypothesize  that  global 
effects  on  the  many  channel  functions  —  yet  to  be 
explored—account  for  the  clinical  presentation.  Other 
genetic or epigenetic factors might account as well for 
inter- and intrafamilial variability.
In our work, both children having mutations in  TRPV4 
presented  laryngeal  stridor,  with  a  documented  vocal 
fold  paralysis  in  the  eldest  and  more  severe  patient. 
None  of  the  remaining  cases  screened  for  TRPV4 
variants  showed  vocal  cord  involvement  nor  hoarse 
voice  or  cry.  Involvement  of  laryngeal  muscles is  not 
frequent  in hereditary  motor-neuropathies  but  it  is 
seldom  associated  with  recessive  mutations  in  the 
ganglioside induced differentiation-associated protein 1 
gene (10),  with dominant  variants in  the early growth 
response 2 gene (11), dynactin 1 (12), and in a form still 
awaiting  gene  cloning  on  chromosome  2q14  (13). 
Clinical  differences  between  the  aforementioned 
phenotypes  and  dSMA  or  SPSMA  are  easyand 
straightforward (14). A second conclusion of the present 
work is that presence of complete vocal cord paralysis 
or  hoarse  voice  should  alert  on  a  possible 
TRPV4-pathy,  especially  when  a  subtle  or  manifest 
bone  involvement  is  present.  Interestingly,  TRPV4 
channels are also expressed in the epithelium of upper 
respiratory  tract  airways  including  trachea  and  larynx 
(15) but it remains uncertain the relationship with vocal 
cord paresis. 
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1.2 A novel mutation in DYNC1H1 bridges the  
gap  between  motor  neuropathy  and  neuronal  
migration defect
by  Guja  Astrea,  Chiara  Fiorillo,  Francesca  Moro,  F.M. 
Santorelli, R. Battini 
manuscript in preparation 
Introduction
Mutations  in  DYNC1H1,  encoding  the  heavy  chain 
protein  of  the  cytoplasmic  dynein  1  motor  complex, 
which plays a key role in retrograde axonal  transport, 
have  recently  been  reported  in  a  large  autosomal 
dominant axonal CMT (CMT-2O) (1) family and in three 
families with congenital SMA-LED (2). De novo variants 
have also been detected in  two unrelated cases with 
severe intellectual impairment, abnormal lobe gyration, 
and cortical dysplasia (3).
We  are  going  to  describe  clinical,  molecular  and 
imaging  findings  in  a  young  man  with  features  of 
congenital  dSMA,  global  developmental  delay,  and 
abnormal lobe gyration. Due to recent clinical findings 
and mice model  observations, we performed full  gene 
scanning of DYNC1H1 discovering a novel mutation.
Case report
This 19-year-old patient presented at birth with bilateral 
foot  malformation  and  amniotic  bands  affecting  the 
lower  limbs. Global  development  was  delayed:  he 
walked independently at 22 months and spoke his first 
words  at  36  months.  Neurological  examination  at  5 
years disclosed lower limb weakness with waddling gait 
and positive Gowers’ maneuver. Tendon reflexes were 
generally brisk with ankle clonus, while patellar reflexes 
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were  reduced.  The  plantar  response  was  extensor. 
Electromyography  showed  increased  amplitude  and 
frequency  of  motor  unit  potentials, whereas  nerve 
conduction  velocity  (NCV)  studies  were  normal.  A 
muscle  biopsy  confirmed the  presence  of  neurogenic 
damage. The latest neurological examination, at age 19 
years,  showed  waddling  gait  with  pes  cavus.  KAFO 
orthoses  were  worn  to  support  ambulation. 
Hyperlordosis  and  right  curve  scoliosis  were  also 
present.  The  lower  limbs  were  weak  and  distally 
atrophied,  and  appeared  disproportionately  short 
compared  to  the  trunk  and  upper  limbs,  which  were 
spared.  Patellar  reflexes  were  reduced,  ankle  clonus 
was  present  bilaterally  and  plantar  responses  were 
mute.  The  patient  reported  painful  paresthesia. 
Vibratory but not touch sensation was severely impaired 
in  the  lower  limbs. Mild  cognitive  impairment  was 
detected,  especially  in  verbal  skills.  Depression  and 
generalized  anxiety  disorder  were  also  present.  An 
electroencephalogram  showed  nonspecific 
abnormalities,  although  the  patient  has  never 
manifested seizures.  NCVs were  again  normal.  Brain 
MRI revealed bilateral dilatation of anterior sylvian areas 
as  due  to  widening  of  the  temporal  opercula,  and 
abnormal gyration of the right frontal lobe (Figure 1A-C). 
Muscle  MRI  strongly  resembled  previously  reported 
dSMA cases (4) showing a pattern of diffuse atrophy of 
the  thigh  muscles  with  relative  hypertrophy  of  the 
adductor longus and semitendinosus (Figure 1D).
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Figure 1 
Brain MRI  in  the  patient.  (A)  Axial  T2-weighted,  (B)  Axial 
T1-weighted  FLAIR  and  (C)  coronal  T2-weighted  brain 
neuroimaging  features  in  a  patient  presenting  a  novel 
mutation  in  DYNC1H1 show  slight  frontal  cortical  atrophy, 
bilateral dilatation of anterior sylvian areas as due to widening 
of temporal opercula (arrows), and abnormal gyration of the 
right frontal lobe (circle).  (D) Transverse T1-weighted MRI of 
thigh muscles shows extensive fatty atrophy preserving the 
medial compartment with hypertrophy of the adductor longus 
(al) and semitendinosus (st).
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Molecular  alterations  in  known genes associated with 
motor neuropathies as well as in SMN1 had been ruled 
out during the disease course.  We performed full gene 
scanning of  DYNC1H1,  and identified a heterozygous 
c.3581A>G/p.Q1194R variant.  The novel mutation lies 
in the N-terminus tail of cytoplasmic dynein 1; it was not 
detected in 500 control chromosomes nor in large SNP 
databases, and it arose  de novo in the family. Alamut 
2.1  (Interactive  Biosoftware,  Rouen,  France)  and 
Polyphen2  analyses  predicted  the  mutation  to  be 
deleterious to normal protein function.
Discussion 
Cytoplasmic  dynein  1 is  a  multisubunit  motor  protein 
that is driven along microtubules by energy derived from 
ATP hydrolysis. It is involved in a variety of fundamental 
cellular processes, including organization of the mitotic 
spindle, positioning of many intracellular organelles and 
retrograde axonal transport (5). The dynein heavy chain 
protein,  encoded by  DYNC1H1,  forms the core of the 
complex, homodimerizing via its N-terminal tail domain. 
As in SMA-LED and CMT-2O, the p.Q1194R is located 
in  the  tail  domain,  also  thought  to  serve  for  binding 
associated proteins.  One such protein  is  LIS1 whose 
haploinsufficiency  causes  severe  human  neuronal 
migration  disorder  (6).  Thus,  the  combination, 
documented  in  our  patient,  of neurodevelopmental 
abnormalities  and  a  distinctive  pattern  of  muscular 
atrophy seems to encompass the different features of 
the peripheral  and the central  nervous system (CNS) 
involvement to date associated with mutated DYNC1H1 
in human and mouse models. 
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2 Identification of a new form of Neutral Lipid 
storage Disease
Neutral lipid storage diseases (NLSDs) are multisystem 
lipid  disorders  due  to  a  defect  either  in  the  adipose 
triglyceride lipase (ATGL) or in the alpha/beta-hydrolase 
domain-containing  protein  5  (ABHD5)  (1,2).  ABHD5 
activates  ATGL,  which  catalyzes  the  first  step  in  the 
hydrolysis  of  triacylglycerol  to  produce  free  fatty  acid 
and  diacylglycerol.  Mutations  in  PNPLA2,  the  gene 
encoding ATGL, cause NLSD with myopathy (NLSDM, 
OMIM # 610717) (3), whereas mutations in the CGI-58 
gene, coding for ABHD5, cause NLSD with ichthyosis 
(NLSDI),  also  termed  Chanarin–Dorfman  syndrome 
(CDS, OMIM # 275630) (2,4).
The hallmark of both diseases is the presence of neutral 
lipid  droplets  storage  in  multiple  tissues,  including 
skeletal muscle and leukocytes.
Here, we report clinical, morphological, MRI and genetic 
findings  of  a  boy  carrying  mutations  in  PNPLA2  and 
massive lipid storage in a muscle biopsy without overt 
muscle  symptoms  except  for  persistently  markedly 
elevated  serum  CK  levels.  These  findings  show  the 
importance to pay more attention on every clinical sign 
and confirm the role of muscle MRI for early muscular 
diagnosis. 
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2.1 Subclinical myopathy in a child with neutral  
lipid  storage  disease  and  mutations  in  the  
PNPLA2 gene
by Chiara Fiorillo, Giacomo Brisca, Denise Cassandrini, Sara  
Scapolan,  Guja  Astrea,  Maura  Valle,  Francesca  Scuderi,  
Federica  Trucco,  Andrea  Natali,  Gianmichele  Magnano,  
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Introduction
CDS/NLSDI  is  characterized  by  the  presence  of 
ichthyosiform  nonbullous  erythroderma.  Slowly 
progressive  weakness  of  proximal  limb  muscles  with 
raised serum muscle enzymes can be detected in about 
60% of cases. Hepatomegaly, various ocular symptoms 
(cataract,  nystagmus,  and  strabismus),  hearing  loss, 
mild mental retardation, short stature, microcephaly and 
intestinal involvement are also described (4,5).
Patients with NLSM start complaining of limb weakness 
at the beginning of the third decade of life despite lipid 
accumulation  most  likely  precedes  the  clinical 
symptoms (6,7).  Serum CK is  always highly  elevated 
(up to 50-fold normal values) and occasionally can be 
the only sign in childhood as seen in an asymptomatic 
18-year-old-girl (8). 
The  course  of  the  disease  is  slowly  progressive  and 
cardiomyopathy may develop at later stages in half of 
the patients.  No ichthyosis  is  present  and neither  the 
central nor the peripheral nervous systems are involved 
(1,8). 
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Case report
The  propositus  is  a  14-year-old  boy,  the  first  child  of 
healthy nonconsanguineous Italian parents.
He  was  born  at  term  by  normal  delivery  after  an 
uncomplicated  pregnancy.  His  motor  milestones  were 
normal.
At  five  years  of  age  he  was  referred  to  our  Center  for 
additional  evaluation  of  elevated  levels  of  serum  CK 
discovered during a routine blood test. Family history was 
negative for neuromuscular disorders. His younger brother 
is healthy.
General physical examination was normal and the patient 
denied the occurrence of myalgia or cramps. Neurologic 
examination did not reveal any muscle weakness or CNS 
impairment.  Muscle  tone,  and  strength  were  normal  for 
age and there  was no calf  hypertrophy  or  contractures. 
Serum CK was 1200 U/l  (normal values less than 150), 
while  routine  laboratory  investigations  and  screening  for 
metabolic disorders were normal. Electromyography of the 
anterior  tibialis  muscle  showed  myogenic  signs,  while 
nerve conduction studies were normal. EKG was normal.
In keeping with the national guidelines on the diagnostic 
approach to  asymptomatic  hyperCKemia (9),  the patient 
underwent  a  muscle  biopsy  after  obtaining  parental 
informed written consent.
The  biopsy  specimen  was  taken  from  the  quadriceps 
muscle and processed according to standard techniques 
for  routine  histology  and  histochemistry.  We  detected 
multiple neutral lipid vacuoles in both fibers type I and II. 
Neither necrotic or ragged-red fibers nor rimmed vacuoles 
were observed. Glycogen was normal.
Total  and  free  carnitine  dosage  in  blood  and in  muscle 
homogenate  was  normal.  Carnitine  palmitoyltransferase 
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(CPT)  determination  and  respiratory  chain  enzyme 
analysis in muscle homogenate were normal.
In  the  following  years,  the  patient  had  variably,  but 
persistently elevated serum CK levels. His clinical picture 
remained  stable  and  muscle  performances  were  in 
keeping with his peers.
Routine laboratory investigations, including cholesterol and 
triglycerides, were again normal.  Peripheral  blood smear 
showed  the  presence  of  lipid  droplets  in  the  patient’s 
leukocytes.  Liver  and  heart  ultrasound  were  normal,  as 
well  as  brain  MRI  spectroscopy.  Oral  test  glucose  was 
normal whilst euglycemic clamp showed a severe hepatic 
and a mild peripheral insulin resistance.
MRI  of  skeletal  muscle,  including  whole  body  coronal 
T1-weighted, axial T1-weighted sequences in lower girdle 
muscles, thighs and lower legs, and in-phase and out-of 
phase scans of the legs, was performed on a 1.5-T MR 
system  (Achieva  Intera, Philips  Medical  System, 
Eindhoven, Nederland) using standard protocols (7,10).
Genomic  DNA  was  obtained  from  peripheral 
lymphocytes  using  a  standard  salting-out  technique. 
The  entire  coding  regions  and  the  exon–intron 
boundaries of the PNPLA2 gene were PCR-amplified, 
and directly sequenced using BigDye 3.1 chemistry on a 
multicolor  fluorescence-based  DNA  analysis  system 
(ABI Prism 3100 Genetic Analyzer; Applied Biosystems, 
Foster City, CA).
Results and discussion
A muscle biopsy  performed in an asymptomatic  child 
with  elevated  levels  of  serum  CK  when  he  was 
5-years-old, showed a lipid storage myopathy. Dosage 
of free and total carnitine, carnitine palmitoyltransferase 
and respiratory chain enzymes were all normal.
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At  that  time,  the  clinical  condition  remained 
undiagnosed. In the following years, the identification of 
the  PNPLA2  gene  (3)  prompted  us  to  revaluate  the 
diagnostic approach. A simple peripheral blood smear 
revealed  the  presence  of  lipid  accumulations  in 
granulocytes (the so-called Jordans anomaly) leading to 
a possible diagnosis of NLSM. Moreover, muscle MRI 
images in our patient were similar to previous report (7) 
and  consistent  with  a  prevalent  fatty  degeneration  of 
gluteal  muscles  and  posterior  thigh  and  leg  muscles 
with  a  relative  sparing  of  the  anterior  compartments, 
further  contributing  to  define  a  selective  pattern  of 
muscle involvement in NLSM (Figure 1).
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Figure 1
                  
(A)  Coronal  T1-weighted  slices  showed  prominent  fatty 
degeneration in gluteal muscles, posterior thigh and posterior 
leg muscles with sparing of upper girdle muscles. (B) At thigh 
level, MRI showed predominant involvement of the posterior 
compartment with marked fatty infiltration of adductor magnus 
(Am), semimembranous (Sm) and biceps femoris long head 
(Bl). Quadriceps muscles (Rf, Vl, Vi, Vm) and semitendineous 
(St) appear to be spared. (C) At lower leg level moderate fatty 
infiltration of medial gastrocnemius (Gm) and soleus (S) in the 
posterior compartment was evident with hypotrophy of lateral 
gastrocnemius (Gl).  Mild hyperintense signal changes were 
present in anterior compartment muscles, tibialis anterior (Ta) 
and extensor longus digitorum and hallucis (Ex) with sparing 
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of  tibialis  posterior  (Tp).  (D  and  E)  Using  out-of  phase 
imaging, at thigh and leg level fatty degeneration is reflected 
by loss of  signal intensity in the same muscles.  In anterior 
compartment  of  the  leg,  more evident  abnormalities  in 
anterior compartment (Ta, Ex), compared to T1 sequences, 
were present. (F and G) Patterns of muscle involvement in 
neutral lipid storage disease with myopathy (NLSDM), based 
on the literature data and our experience. The replacement of 
muscle tissue by fat is reflected by the dark gray color of the 
muscle.  Initial  and/or  variable involvement of  the muscle is 
represented by the light gray color.  The white color means 
spared muscles.
However,  in  our  child,  minimal  changes  in  anterior 
compartment of the leg were already detectable in an 
early  and  asymptomatic  stage  of  the  disease.  These 
findings were highlighted using out-of-phase scans so 
underlying  the  importance  of  this  technique  in  lipid 
storage  myopathies  (11).  Expectedly,  analysis  of 
PNPLA2  in  the  patient’s  genomic  DNA  detected  two 
heterozygous mutations,  a nonsense C>T mutation at 
nucleotide  865  (c.865C>T)  in  exon  7,  predicting 
premature protein truncation at codon 289(p.Q289X) on 
the paternal  allele  and a novel  missense mutation  at 
nucleotide 424 (c.424A>T, p.N142Y) in exon 4 on the 
maternal allele (Fig. C). The latter variant was scored to 
be  predictably  deleterious  to  protein  function  in  silico 
(Polyphen2,  genetics.bwh.harvard.edu/pph/),  and  was 
absent in 200 healthy Italian chromosomes or in large 
SNP  databases  (NHLBI  Exome  Sequencing  Project, 
evs.gs.washington.edu/EVS/).
To the best of our knowledge, NLSM has been reported 
in  22  cases,  and  17  mutations  have  been  identified 
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throughout  the entire PNPLA2 gene (3,7,8,12-19).  On 
clinical ground, the NLSDM phenotype is characterized 
by  proximal,  often  asymmetric,  muscle  weakness  in 
both upper  and lower  girdle  muscles  starting  in  early 
30’s,  a  presentation  highly  resembling  limb  girdle 
muscular  dystrophies  (LGMD).  Distal  involvement  of 
finger extensors and foot flexors can manifest later in 
the  disease  course.  In  all  the  patients  serum  CK  is 
elevated  (around  5-fold)  and  laboratory  investigations 
might reveal hypertriglyceridemia. A few cases develop 
diabetes mellitus. To date, one case of NLSM has been 
reported at young age, namely in a 18-year-old-girl that 
was  asymptomatic  for  myopathy  presenting  only 
elevated CK levels (8). Here we report a NLSDM case 
detected  in  childhood  without  clinically  evident 
myopathy  but  only  hyperCKemia.  This  finding  may 
further support the notion that hyperCKemia is the early 
sign of NLSDM in childhood preceding the manifestation 
of clinical overt myopathy.
PNPLA2 gene encodes for ATGL, a hormone-sensitive 
lipase  that  catalyzes  the  initial  step  in  triglyceride 
hydrolysis  in  mammalian  adipose  tissue.  At  its 
N-terminal, ATGL contains a ‘patatin domain’ common 
to the acyl-hydrolases while at the C-terminal it displays 
an  hydrophobic  region  responsible  to  bind  the  lipid 
droplets (3). Most of the reported mutations of PNPLA2 
gene are nonsense and affect the C-terminal domain of 
the  gene  (residues  252–504)  and  particularly  the 
hydrophobic  region  (lipid  binding  domain  residues 
309–391).  Interestingly,  our  patient  carried  a  novel 
missense  mutation  in  the  patatin-like  phospholipase 
domain (PLPD) (residues 10–179), and a nonsense in 
the C-terminus. The latter has been previously reported 
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in homozygosis in an Algerian family in association with 
typical  late-onset lipid storage myopathy and classical 
distribution of  muscular  weaknesses,  In contrast,  only 
two mutations (8,12) have been identified in the PLPD 
domain  which  affects  the  lipase  activity,  Given  the 
limited penetrance observed in our patient, and in the 
absence of more functional tests, we can only speculate 
that the new c.424A>T/p.N142Y alone or in combination 
with other yet unknown factors – including the patient’s 
genetic  background  –  could  protect  his  muscle  from 
being  weak  and  atrophic  notwithstanding  the 
accumulation of lipids, possibly increasing the function 
of  the  ATGL  protein  coded  from  the  non-truncated 
allele.
Although no effective therapy is currently available for 
NLSM, encouraging results have recently been showed 
in patients’ cells upon treatment with a beta-adrenergic 
agent,  thought  to  activate  alternative  pathway  of 
triglyceride metabolism (7).
In  conclusion,  we  have  genetically  characterized  a 
14-year-old  boy  with  hyperCKemia  and  a  subclinical 
myopathy due to neutral lipid storage.
Search for lipid droplets in peripheral leukocytes and the 
PNPL2 gene analysis should be added to the diagnostic 
work-up of patients with hyperCKemia (20).
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3 Difficult orientation approach in CMD-LGMD: 
the genetic point of view
Congenital muscular dystrophy (CMD) is a clinically and 
genetically  heterogeneous  group  of  inherited  muscle 
disorders.  Muscle  weakness  typically  presents  from 
birth to early infancy. 
The main CMD subtypes, grouped by involved protein 
function and gene in which causative mutations occur, 
are  laminin  alpha-2  (merosin)  deficiency  (MDC1A), 
collagen  VI-deficient  CMD,  the  dystroglycanopathies 
(caused  by  mutations  in  POMT1,  POMT2,  FKTN, 
FKRP, LARGE, POMGNT1, and ISPD), SEPN1-related 
CMD  (previously  known  as  rigid  spine  syndrome, 
RSMD1) and LMNA-related CMD (L-CMD). Several less 
known CMD subtypes have been reported in a limited 
number of individuals. With the discovery of causative 
mutations in the last two decades, the concept of CMD 
has evolved from a narrowly defined clinical diagnosis 
(onset in the first months of life) and histologic diagnosis 
(dystrophic muscle on biopsy) to a more inclusive group 
of  subtypes  defined  by  genes  in  which  causative 
mutations  occur.  No  complete  or  satisfactory 
classification  system  exists;  furthermore,  phenotypes 
overlap  both  within  CMD  subtypes  and  among  the 
congenital  muscular  dystrophies,  congenital 
myopathies,  and  limb-girdle  muscular  dystrophies. 
Nonetheless, the umbrella term CMD remains useful by 
providing  a  framework for  the  diagnostic  approach to 
the infant or young child with muscle weakness.
The  assumptions  here  below  are  a  part  of  a 
collaboration project involving Dubowitz Neuromuscular 
Centre (London).  
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Introduction
Congenital  muscular  dystrophies  (CMD)  are  a  highly 
heterogeneous  group  of  conditions  caused  by 
alterations in more than 12 genes involved in several 
and  not  completely  understood  pathogenetic 
mechanisms (1). 
CMD are characterized by muscle weakness since birth, 
or  shortly  after,  and  variable  clinical  manifestations 
affecting the eye and the central nervous system. Some 
of  these  disorders  are  fatal  in  the  first  year  of  life, 
whereas others have a milder course, and progression 
into adulthood (2).  
The  diagnosis  of  CMDs  requires  a  multidisciplinary 
expertise  (neurology,  morphology,  genetics, 
neuroradiology)  that  is  available  in  a  few  centres 
worldwide  with  sufficient  experience  in  the  different 
CMD. Currently, achieving a full molecular diagnosis in 
CMD is of paramount importance not only for improved 
phenotype-genotype  correlations,  better  genetic  and 
prenatal  counselling,  prognosis  and  aspects  of 
management,  but  also  because  of  the  imminent 
availability of clinical trials and treatments (2).
There is no complete and satisfactory classification in 
CMD. Following the initial definition of forms based on 
clinical  features  and  country  of  origin,  it  was  soon 
recognized  a  significant  overlap  of  features  and  an 
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ample genetic heterogeneity. A more modern molecular 
classification  recognizes  forms  on  the  basis  of  the 
involved  protein  function  and the  gene  in  which 
causative  mutations  occur.  Thus,  we  consider  the 
following subtypes: laminin alpha-2 (merosin) deficiency 
(MDC1A),  collagen  VI-deficient  CMD,  the 
dystroglycanopathies (caused by mutations in  POMT1, 
POMT2,  FKTN,  FKRP,  LARGE  and POMGNT1), 
SEPN1-related CMD (previously  known as rigid spine 
syndrome,  RSMD1) and  LMNA-related CMD (L-CMD) 
(3). Several less known subtypes have been reported in 
a  limited  number  of  individuals.  However,  even  with 
current  molecular  tools,  approximately  25-50%  of 
patients remain without an identifiable genetic mutation 
and further heterogeneity is  expected (4).  In addition, 
information  on  incidence  and  prevalence  of  CMD  is 
scanty  because  of  the  lack  of  diagnostic  genetic 
confirmation  before  the  identification  of  the  several 
causative genes. Few studies, however, have defined a 
prevalence ranging from 0.68 to 2.5 per 100,000, which 
is  probably  underestimated  (5). Moreover,  founder 
mutations are known to occur, such as the insertion of a 
3-kb  retrotransposon  element  in  the  3’  untranslated 
region of  fukutin (FKTN) reported in Japanese patients 
with Fukuyama-type CMD (FCMD) (6).  All  these data, 
however, provide only a limited information rather than a 
real  figure  of  incidence  or  prevalence.  With  several 
genetic  ethologies  being  offered  in  diagnostic 
neurogenetic  laboratories,  it  is  possible to draw more 
precise figures of the molecular prevalence of CMD.
This retrospective review reports the genetic breakdown 
in a CMD population referred for a genetic work-up at 
the  Dubowitz  Neuromuscular  Centre.  Our  aim  is  to 
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describe the relative frequency of CMD subtypes in this 
patient population and the relative frequency of different 
type of mutations among different genes,  commenting 
on  novel  mutations  and  summarizing  the  genetic 
variation that occurs in the CMD-associated genes.
Patients and methods
Patients
The Dubowitz Neuromuscular Centre is the UK National 
Commissioning Group referral centre for CMD. 
About 600 DNA samples obtained from peripheral blood 
from UK patients regularly  assessed by the Dubowitz 
Neuromuscular  Centre  or  forwarded  to  us  for  a 
confirmatory  molecular  diagnosis  of  ‘possible  CMD’ 
have  been  analysed  between  2001  and  2011  and 
represented  the  whole  study  cohort.  We  focus  our 
attention to data from 331 of 600 (55%) index cases in 
289  unrelated  families  for whom  a  pathogenetic 
mutation  in  know  CMD  genes  was  detected. When 
more  than  one  affected  member  of  a  family  was 
available, we focus our analyses only on the proband. 
Written informed consent was obtained from each family 
prior  to testing, and this project  was approved by the 
relevant local ethics committee. 
Molecular genetic studies
Molecular genetic analysis of CMD genes was provided 
by Guys and St Thomas’ Trust, London (part  of  CMD 
NCG service) and the NCG Referral Centre for LGMD 
at  the  Institute  of  Human  Genetics  at  Newcastle 
University. The entire coding regions of the 11 known 
CMD genes (namely, LAMA2, COL6A1-A2-A3, POMT1, 
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POMT2,  POMGNT1,  FKRP,  FKTN,  LARGE,  ISPD, 
SEPN1,  LMNA) including splice sites, were sequenced 
in blood DNA in all patients. 
For the patients  in  whom we identified mutations,  we 
also  tested  available  family  members  for  the  specific 
mutations  and  any  variants  of  unknown  significance 
(VUSs) by direct Sanger sequencing. 
All  the  variants  identified  were  investigated  in  silico 
using  Alamut  v1.5  (Interactive  Biosoftware, 
http://www.interactivebiosoftware.com/).  This  software 
incorporates  several  prediction  algorithms  including 
SpliceSiteFinder,  MaxEntScan,  NNSPLICE, 
GeneSplicer,  as  well  as  variant  scoring  methods  — 
namely, PolyPhen2, SIFT, and Align GVGD. Alamut v1.5 
also examines the conservation of both the nucleotide 
and amino acid residue across 11 species, and includes 
a search of previously reported variants in the literature. 
Based  on  in  silico findings,  literature  searches,  and 
revision  of  data  in  dbSNP 
(http://www.ncbi.nlm.nih.gov/snp/),  all  variants  were 
divided  into  “mutations,”  “polymorphisms,”  or  “VUSs.” 
Variants were classified as “polymorphisms” if they were 
listed in dbSNP with an MAF (minor allele frequency) of 
5%  or  greater  in  a  sufficient  number  of  control 
chromosomes. Variants were classified as VUSs if there 
was no convincing evidence that they had a causative 
effect  or  were  polymorphic.  VUSs  included  both 
synonymous and nonsynonymous changes not listed in 
dbSNP; variants listed in dbSNP with a MAF <5% and 
also  variants  where  the allele  frequency  was  derived 
from testing only a very small number of chromosomes. 
VUSs also included some intronic variants that were not 
predicted to affect splicing. We classified novel variants 
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as “mutations” if any of these conditions occurred: they 
affected a moderate to highly conserved nucleotide, or a 
highly  conserved  residue,  and  if  the  resulting 
physiochemical difference of  the wild-type and mutant 
amino acid was at least moderate.
Results
In  the  289  CMD families  included  in  this  study  (331 
patients), the most common diagnosis was collagen VI 
related –CMD (32,18%), followed by merosin deficient 
-MDC1A (29,41%),  dystroglycanopathy  (24,56%)  and 
selenoprotein 1-RSMD1 (13,84%) (see Figure 1). 
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dystroglycanopathy
MDC1A
RSMD1
CollagenVI-related 
disorders
Collagen VI mutations
The COL6 protein is composed of three different subunit 
α-chains  encoded  by  the  3  genetically  distinct  genes 
COL6A1 (on chromosome 21q22.3), COL6A2 (22q23.3) 
and COL6A3 (2q37). 
The COL6A1 gene spans 29 kb and contains 35 exons. 
The encoded protein measures 1028 amino acids with a 
predicted molecular mass about 108kD. 
The COL6A2 gene spans 36 kb and contains 30 exons. 
The encoded  protein  is  998  amino acids  long  with  a 
calculated molecular mass about 140kD. 
The COL6A3 gene spans 90 kb and contains 43 exons. 
The encoded protein is made of 3177 amino acids with 
a calculated molecular mass of > 300kD. 
Mutations  in  COL6  genes  may  cause  three  muscle 
diseases:  Ullrich  congenital  muscular  dystrophy 
(UCMD),  Bethlem  myopathy  (BM)  and  autosomal 
recessive  (AR)  myosclerosis  myopathy.  UCMD  was 
initially  regarded  as  an  exclusively  AR  condition; 
however,  a  few  years  later,  patients  were  reported 
harbouring  heterozygous  mutations  in  COL6A1  and 
COL6A2.  BM is a relatively milder autosomal-dominant 
(AD)  disorder  linked  to  all  COL6  genes  but  recent 
studies  identified  recessive  mutations  in  COL6A2 
associated with the BM phenotype. It is current opinion 
that UCMD and BM cannot be considered as separate 
clinical entities, but they rather represent a continuum 
ranging from severe UCMD to mild BM phenotypes with 
patients  showing  intermediate  phenotypes  considered 
to have either “mild UCMD” or “severe BM” (7,8).
Mutations  spanning  the  COL6A1-A2-A3  genes  have 
been  identified  in  104  index  cases  (31,42% of  total) 
from 93 families  manifesting a spectrum ranging from 
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the most severe UCMD to the mildest BM. Forty families 
carried  mutations  in  COL6A1,  24  in  COL6A2,  29  in 
COL6A3.  Both AD and AR inheritance were detected 
with AD more common in COL6A1 and COL6A3 (31/40 
and  23/29,  respectively)  and  AR  in  COL6A2 (18/24 
kindred). 
COL6A1
In  a  total  of  44  patients  (40  families),  molecular 
analyses  identified   (31  families)  with  pathogenic 
heterozygous mutations in  COL6A1  whereas 9 cases 
harboured  homozygous  mutations.  Whilst  a  clear  AR 
pattern  of  inheritance  was  documented  in  a  single 
kindred,  a  parent-to-son  transmission  was  seen  in  4 
families only, with an asymptomatic parent transmitting 
the  mutated  allele  to  his  affected  son  in  a  single 
instance.  In  a  single  family,  two  allegedly  severe 
mutations  (c.859G>C/p.Gly287Arg  and 
c.931-1G>C/p.Ala420Glyfs)  were  found  in  cis  and 
related  to  a  different  clinical  expressivity  between  a 
father and a son. 
We  identified  a  total  of  21  putatively  dominant 
mutations,  16 of  which were  novel.  Among recurrent 
mutations,  the  described  c.1056+1G>A  was  found  in 
three  unrelated  families  (four  patients)  and  the 
868G>A/p.Gly290Arg  and  850G>A/p.Gly284Arg  was 
seen in four families each. Of 16 novel mutations,  two 
were a deletion affecting the splice site sequences, 9 
were  substitutions  affecting  the  canonical  sites  for 
splicing,  and  5  were  missense.  Among  the  latter, 
c.877G>A/p.Gly293Arg  was  found  in  three  putatively 
unrelated families (a total of 5 patiens). Mutations were 
widely scattered in all exons and introns, though exon 
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10 (n= 5/21 mutations)  and intron 13 (n= 4/21)  were 
predominantly  involved.  Splice  site  substitutions  and 
missene substitutions were the most common mutations 
reported in  our  cohort  (10/21 and 9/21,  respectively). 
Revision  of  available  clinical  data  of  22  patients 
suggested that 13 could be classified as UCMD, 7 as 
BM,  and  2  had  an  intermediate  phenotype.  Seven 
recessive  mutations  were  identified,  6  of  which  were 
novel,  and  included  deletions  (n=  4,  1  in  frame,  3 
frameshift)  and  splice  site  substitutions  (n=2).  The 
c.1272+1G>A was found in three unrelated families and 
the c.1660delG/p.Asp554fs in two not linked families.
Mutations  were  widely  scattered  in  all  exons  and  
introns.  Deletion  and splicesite  substitutions  were the 
only mutations reported in our cohort.  All the patients  
for whom clinical charts could be reviewed (n= 6) were  
UCMD.  
   
COL6A2
In  a  total  of  25  patients  (24  families)  we  detected 
mutations in  COL6A2. Dominant mutations occurred in 
6 families but a clear AD pattern was seen in 5 only. 
Conversely, we found recessive changes in 18 kindred 
(19 patients); an AR inheritance was documented in a 
single case. 
Overall,  we  discovered  6  novel,  putatively  dominant 
mutations (5 splice site  substitution or  deletion and 1 
missense),  of  which 4 were in intron 5. Fifteen of  19 
likely  recessive  mutations  were  novel  and  included 
deletions (n=10, of which 5 were in frame and 2 large 
deletions), missense (n= 3) and nonsense (n= 2). The 
homozygous  c.2329T>C/p.Cys777Arg  recurred  in  two 
unrelated  patients  whereas  the  homozygous 
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c.2839_2850del/p.Leu947_Gly950del  was found in four 
unrelated  kindred  and  the c.1660_1668del/p.  
Lys554_Glu556del  was  homozygous  in  one  and  in 
compound heterozygosity in another family. Recessive 
mutations were scattered throughout the gene with exon 
26  (n=  3)  and  exon  28  (n=  5)  being  more  affected. 
Deletions appeared more common than other types of 
changes in COL6A2.
COL6A3
In  a  total  of  35  patients  (29  families)  we  detected 
mutations  in  COL6A3,  dominant  in  29  patients  (23 
families)  and  recessive  in  6  cases.  We  could 
documented an AD inheritance in 7 families, and an AR 
pattern in 5 families.  
Eighteen of 21 putative dominant mutations were novel 
(6  deletions,  3  splice  site  mutation  and 9  missense). 
The  described  c.6210+1G>A and  the  new 
c.6212G>A/p.Gly2071Asp recurred each in two families. 
Mutations  were  widely  scattered  in  all  exons  and 
introns,  though  exon  17  was  involved  predominantly, 
missense and deletions were the most common in our 
cohort  (9/21  and  6/21,  respectively).  Eigh  novel 
mutations (1 frameshift deletion, 1 deletion at splice site, 
4 missense, and 2 nonsense) were allegedly recessive 
with the  7447A>G;/p.Lys2483Glu  being more frequent 
(three unrelated kindred). 
Mutations were prevalent in exon 36 and 38 (each with  
3 variants)  and missense substitutions were relatively  
more frequent in our cohort (4/8).  
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LAMA2 mutations
The laminin alpha-2 gene (LAMA2) encodes the heavy 
α2  chain  of  the  laminin  211  isoform  (α2/β1/γ1)  also 
termed merosin, it is localised on 6q22-23, spans about 
633  kb  of  genomic  DNA  and  contains  65  exons. 
LAMA2-deficient  CMD  has  an  autosomal  recessive 
inheritance  and  is  a  severe  form  presenting  with  an 
absence  of  laminin  alpha-2  (merosin)  around  muscle 
fibres, high serum creatine kinase (CK) levels especially 
in  early  life,  no  independent  ambulation  due  to 
weakness  and  contractures,  and  a  respiratory 
insufficiency which often requires tracheotomy (9). Most 
patients  have  normal  intelligence  but  some  show 
moderate mental retardation and epilepsy. In contrast to 
less  common  cases  with  partial  merosin  deficiency 
cases,  MDC1  forms  a  clinically  homogeneous 
subgroup.  Diagnosis  is  usually  made  by  the  clinical 
features  and  a  muscle  biopsy  examination  (complete 
LAMA2 deficiency can also be determined using a skin 
biopsy)  (10).  In  a  sample  from  north-east  Italy,  the 
prevalence  of  CMDs  has  been  estimated  to  be 
0.7/100,000  (5). LAMA2-deficient  CMD  accounts  for 
about  30% of  the CMD cases in  European countries, 
but only 6% in Japan (6).
In  our  cohort,  we  identified  LAMA2 mutations  in  94 
patients  (28,40%) in  85  families.  Forty-six families 
carried  a  compound heterozygous  mutation  while  the 
remaining  39  had  a  homozygous  mutation.  Multiple 
affected sibs and a probable AR pattern of transmission 
was seen in 8 kindred. Out of 81 different mutations, we 
found  32  novel  variants,  including  6 missense,  11 
nonsense,  7  frameshift  deletions,  and  7  spice  site 
substitutions.  We also  detected  a  single  synonymous 
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mutation  (c.4860G>A) predictably  affecting  splicing. 
There  were  also  several  recurrent  mutations.  These 
included the reported 2049_2050delAG variant — that 
was  homozygous  in  3  families  and  compound 
heterozygous  in  6  —,  the  5562+5G>C  and  the 
c.2556delT/p.Phe852fs (both found at the heterozygous 
state  in  6  and  7  families,  respectively).  The  novel 
c.3283C>T/p.Arg1095*  and  the  c.1306+2T>G  change 
were  detected  in  two  unrelated  families  (one  in 
homozygousity). 
Mutations  were  widely  scattered throughout  the  gene 
and  nonsense  and splicesite  substitutions  were more 
common (28/81 and 20/81 respectively). Interestingly, 3 
patients  from  2  unrelated  families  had  merosin 
deficiency, linkage data compatible with linkage to the 
6p22.23  region  were  LAMA2 resides,  and  yet  not 
detectable  mutations  in  coding  exons  and  flanking 
intronic sequences.
Mutations  in  genes  related  to 
dystroglycanopathies 
The  groups  of  CMDs  characterized  by  abnormal 
glycosylation  of  alpha-dystroglycan  (aDG)  are 
commonly  termed  alphadystroglycanopathies 
(aDGpathies)  and  include  FCMD  (MIM  253800), 
muscle-eye-brain  disease  (MEB;  MIM:253280), 
Walker–Warburg  syndrome  (WWS;  MIM:236670), 
congenital  muscular  dystrophy  1C  (FKRP-related  or 
MDC1C;  MIM:606612),  and  congenital  muscular 
dystrophy 1D (LARGE-related or MDC1D; MIM:608840) 
as well as the allelic LGMD presentations for most of 
these  genes.  The  underlying  genetic  defects  in  this 
group  of  disorders  are  mutations  either  in  known  or 
79
putative glycosyltransferase enzymes and cooperating 
proteins involving aDG-O-mannosyl-linked glycosylation 
or  subsequent  LARGE-dependent  glycosylation, 
aDGpathies.  The  mutation  frequency  in  the  6  more 
common genes in aDGpathies has been examined in 
two independent large series and ranges from 34% to 
53% indicating that  approximately  half  of  the patients 
with  an  aDGpathy  harbour  mutations  in  still 
undiscovered genes (4, 11). Less studied are mutations 
in ISPD, usually associated with MEB, WWS, as well as 
cerebellar cysts, but seem less common (1).
In our cohort we identified 86 patients (25,98%) in  71 
kindred of which 23 harboured mutations in FKRP, 20 in 
POMGNT1,  12 in  POMT2,  10 in  POMT1,  5 in  FKTN, 
and 1 in LARGE (Figure 2).
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POMT1
POMT2
POMGNT1
FKRP
FUKUTIN
LARGE 
FKRP
The  Fukutin-related  protein  gene  (FKRP)  maps  on 
chromosome19q13.3,  spans  less  than  12.5  kb  and 
contains  4  exons,  but  only  exon 4  is  translated.  The 
encoded  protein  is  495  amino  acid  long,  has  a 
significant  similarity  to  fukutin  and  it  is  a  putative 
glycosyltransferases  probably  localized  in  the  Golgi 
apparatus.  The  range  of  phenotypic  severity  due  to 
FKRP-mutations  is  large  and  includes  MDC1C,  (MIM 
606612),  LGMD2I  (MIM 607155),  CMD,  mental 
retardation  and  brain  abnormalities  (12,13), 
Muscle-Eye-Brain disease (MEB) and Walker-Warburg 
syndrome  (WWS),  as  well  as  asymptomatic 
hyperCKemia without overt muscular involvement.
We found gene variants in 26 patients in 23 families but 
only  in  4 we had a clear AR pattern of  transmission. 
Homozygous mutations  were seen in  11 kindred and 
compound heterozygous changes in  12.  A total  of  18 
different  mutations  were identified  including  10  novel. 
The  recurrent  c.826C>A/p.Leu276lle  change  was 
homozygous in 9 families and was seen in compound 
heterozygousity  in  8.  Novel  mutations  included  7 
missense,  2  nonsense  and  1  frameshift.  The  new 
c.1223G>A/p.Ser408Asn  was  found  in  2  unrelated 
families. Missense substitutions were the most common 
type of gene variants.
POMGNT1
The  O-mannose 
beta-1,2-N-acetylglucosaminyltransferase  protein  gene 
(POMGNT1) maps to  1p34-p33 and codes for  a 660 
amino  acid  protein  that  participates  in  O-mannosyl 
glycan  synthesis.  POMGNT1 gene  is  divided  into  21 
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coding exons and produces a type II  transmembrane 
protein.  Mutations  in  POMGNT1 cause  WWS,  MEB, 
and a milder form of LGMD.
Molecular  studies identified  22 patients  in  20 families 
with recessively inherited mutations,  with  homozygous 
changes in 10. A typical AR segregation could be shown 
in 2 kindred only.  In our cohort we collected 23 different 
mutations,  13  of  which  were  novel.  Of  the  recurrent 
mutations,  the c.1539+1G>A variant was homozygous 
in two families and heterozygous other two kindred. Of 
the  13  novel  mutations,  5  were  missense,  1  was 
nonsense,  3  were  frameshift  deletion,  and  1  each 
duplication,  in-frame  deletion,  insertion,  and 
deletion-insertion.  The  new  c.1832T>C/p.Leu611Pro 
was homozygous in  3  patients  (2  unrelated families). 
Mutations  were  unevenly  distributed  with  2  variants 
each in exon 16, intron 17, and exon 17. Missense (n= 
10)  and splicesite  (n= 4)  substitutions  were the most 
common.
POMT1
The  O-mannosyltransferase  protein  gene  (POMT1) 
maps  to  9q34.1  and  encodes  for  an  enzyme  that 
catalyzes  O-mannosylation  of  proteins,  an  important 
protein modification in eukaryotes that is initiated by an 
evolutionarily  conserved  family  of 
O-mannosyltransferases. The gene contains 20 exons 
and  spans about 20kb. The encoded protein measures 
725  amino  acids  with  a  calculated  molecular  mass 
about 82.5kD. Mutation in  POMT1 cause WWS, MEB, 
and LGMD2K. 
Mutation  analysis  in  our  cohort  identified  10  families 
with  recessively  inherited  POMT1 mutations.  Three 
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families  carried  a  compound  heterozygous  mutation 
whereas  the  remaining  7  harboured  a  homozygous 
mutation. A clear recessive segregation could be proved 
in  a  single  family.  Twelve  different  mutations  were 
identified including 7 novel  (2 missense,  2 nonsense, 
and 1 frameshift  deletion).  No recurrent variants were 
seen in our sample. Mutations were widely scattered in 
all  exons  with  deletions  and  missense  substitutions 
being the more common (5/12 each). 
POMT2
The  O-mannosyltransferase  2  protein  gene  (POMT2) 
maps to 14q24.3 and encodes for an integral membrane 
protein of the endoplasmic reticulum that participates in 
O-mannosyl  glycan  synthesis.  The  POMT2  gene  is 
divided into 21 exons and spans 46 kb. The encoded 
protein measures 750 amino acids. Mutation in POMT2 
cause  MEB,  WWS,  and  LGMD2N  with  mental 
retardation.
Mutation analysis identified 12 families with recessively 
inherited  POMT2 mutations.  Eight  families  carried  a 
compound heterozygous mutation whereas the other 4 
were homozygous,  with a clear recessive segregation 
documented  only  in  two  families.  We  detected  15 
different  mutations,  including  4  new  changes.  The 
described  c.1997A>G/  p.Tyr666Cys  was  found  at  the 
homozygous  state  in  2  families  and  at  heterozygous 
state in two others. Out of the 4 new mutations, 3 were 
missense  and  one  located   at  the  donor  splice-site. 
Mutations  were  widely  scattered  in  all  exons  and 
missense substitutions (12/15) were the most common 
reported.  
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FKTN
The fukutin gene (FKTN) maps to 9q31.2 and encode a 
secreted protein expressed in various tissues in normal 
individuals. FKTN gene is made of 10 exons and spans 
over more than 100 kb. The encoded protein measures 
461 amino acids. Mutation in FKTN can cause a severe 
congenital form with brain and eye anomalies (formerly 
designated FCMD), WWS, MEB, and LGMD2M. A form 
of  dilated  cardiomyopathy  is  also  associated  with 
mutations in FKTN.
We  discovered  5  families  with  recessively  inherited 
FKTN mutations.  Two  families  carried  a  compound 
heterozygous  mutation  whereas  the  other  3  had  a 
homozygous  mutation.  Six  different  mutations  were 
identified,  including  2  novel  (a  missense  and  a 
nonsense change). The described c.1167dupA variant 
was  heterozygous  in  two  unrelated.   Three  variants 
were detected in exon 10. 
LARGE
The  like-acetylglucosaminyltransferase   protein  gene 
(LARGE) maps to 22q12.3 and encodes a bifunctional 
glycosyltransferase that alternately transfers xylose and 
glucuronic acid to aDG, to form a polysaccharide that 
confers the ability to bind ligands (Inamori et al. 2012). 
The  LARGE gene contains 16 exons  and  spans more 
than 664kb. The encoded protein measures 756 amino 
acids.
Mutation  in  LARGE cause  WWS,  MEB,  and  a  less 
severe congenital form with mental retardation, formerly 
designated  congenital  muscular  dystrophy  type  1D 
(MDC1D).
A  single  patient  in  our  cohort  carried  mutations  in 
84
LARGE:  a  described missense substitution  in  exon 9 
and a novel duplication in exon 4. 
Selenoprotein 1 mutations
The  Selenoprotein  1  gene (SEPN1)  maps  to 
chromosome  1p36,  encodes  selenoprotein  N,  a  new 
member of  the selenoprotein family,  which function is 
still unknown.  SEPN1 contains 13 exons including the 
selenocysteine insertion sequence (SECIS) element, a 
secondary  structure  located  in  the  3′  UTR  of  the 
transcript that allows selenocysteine incorporation at a 
UGA codon. The TGA stop codon is in exon 3 and of 
TGA selenocysteine stop codon in exon 10. The gene 
spans  about  18Kb  of  genomic  sequence,  encodes  a 
678 amino acid-long protein with a calculated molecular 
mass  about  70k,  and  it  produces  a 
glycoprotein-localized within the endoplasmic reticulum. 
Mutations  in  SEPN1 cause  a  congenital  muscular 
dystrophy with rigid spine (formerly designated RSMD), 
the  "classical"  form  of  multiminicore  disease,  a 
desmin-related  myopathy  with  Mallory  body-like 
inclusions,  and  a  form  of  congenital  fiber-type 
disproportion. 
We detected recessive SEPN1 mutations in 47 patients 
(14,20%)  from  40  families.  Twenty  families  carried  a 
compound heterozygous mutation while the remaining 
harboured  a  homozygous  mutation.  Only  7  kindred 
presented  with  multiple  affected  sibs  and  a  sure  AR 
transmission.  Of  32  different  mutations  identified,  9 
changes  were  novel.  The  described  recurrent 
c.943G>A/p.Gly315Ser change was found homozygous 
in 5 families and compound heterozygous in 8. Out of 9 
novel mutations, 2 were missense, 1 was a duplication, 
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3 were frameshift deletions, 1 was an insertion, and 2 
were  splicesite  substitutions.  Among  those,  the 
c.1-11_81del92 mutation affected for the first  time the 
5'UTR  sequences.  No  mutations  affected  the  SECIS 
sequences. Mutations were widely scattered in all exons 
and introns but  exons 3 and 8.  Missense substitution 
were the most common (15/32). 
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Discussion
We present here the genetic breakdown in a large cohort 
of UK patients referred to the CMD NCG centre for genetic 
analyses in the past decade (2001-2011). A diagnosis was 
genetically  confirmed  in  48%  of  the  cases  (289/600). 
Within this group, collagen VI related myopathy was the 
most  common diagnosis  with  93/289 patients  (32,18%), 
followed  by  LAMA2 with  85  (29,41%)  and  the 
heterogeneous  dystroglycanopathies  (71  patients; 
24,56%).  Twenty-three  patients  harboured  mutations  in 
FKRP and  20  in  POMGNT1 and  represented  the  most 
common dystroglycanopathies. A diagnosis of RSMD1 was 
made in 40/289 cases (13,84%). 
Our results agree with previous reports (4) where a genetic 
diagnosis was reached in about 46%, and it is higher than 
a  previous  Australian  study  where  a  definitive  genetic 
diagnosis could be made in 24% (14). In the latter study, 
the  dystroglycanopathies  represented the  most  common 
group with 25% of cases, and  collagen VI abnormalities 
were found in 12% (14). In our present as well as in the 
previous study (4) collagen VI related myopathy was the 
most  common  diagnosis.  These  data  are  also  in 
agreement  with  those  of  a  Japanese  population  where 
collagen  6-related  disorders  were  the  second  most 
frequent CMD, following FCMD due to a founder mutation 
in FKTN.
Different  from  data  in  our  previous  study,  mutations  in 
LAMA2 represent  about  28%  of  our  cohort   but  the 
difference may be due to the previous more strict inclusion 
criteria that excluded cases with merosin deficiency whose 
classical presentation make the diagnosis less challenging 
also by first level or second level Centres. Genetic test is 
however possible only on a third level centre and this can 
explain  the  difference  between  the  two  reports. 
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Alpha-dystroglycan  related  dystrophies  represented  the 
third group for frequency in our study. Mutations in FKRP 
(32%),  followed   by  POMGNT1 (28%)  are  the  most 
common,  with  FKRP mutations  more  frequent  in  the 
LGMD. 
The relative frequency of  POMGNT1 mutations is higher 
than the 10% figure gathered in an Italian cohort (11) and 
the  15%  seen  in  another  French  study  in  type  II 
lissencephaly (15).  
Considering  the  frequency  of  POMT1 and  POMT2 
mutations, we have identified 10 (14%) and 12/71 families 
(17%),  respectively.  These  relative  frequencies  are 
diametrically opposite to data observed in the French and 
Italian  studies  (11,  15)  where  POMT1 appeared  to  be 
more common. 
Our  present  study  also  confirmed  a  relatively  high 
frequency of mutations in FKTN, though not as high as in 
Japan where a found mutation account for the significant 
proportion  of  FCMD  (49.2%  of  CMD  cases  in  one 
series) . On the other hand, mutations in LARGE were 
extremely rare in our as in previous studies (4, 11, 15). 
An additional consideration emerging from our analysis 
relates to the frequency of the different aetiologies and 
the amount  of  new mutations  in  the  CMD-associated 
genes.
COL6A
We have identified 40 of 93 families carrying mutations 
in COL6A1, 24 in COL6A2 and 29 in COL6A3, data that 
are partially in contrast with previous reports where a 
high frequency of  mutations in  COL6A1 and  COL6A2 
was reported (7). 
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In  particularly,  in  COL6A1 we  have  identified  a 
significant number of new mutations, both dominant and 
recessive. 
The relatively larger number of dominant compared to 
recessive  mutation  is  in  part  in  agreement  with initial 
reports indicating an association between AD mutations 
in  COL6A1 and  BM (7).  However,  in  our  sample  we 
identified  several  AD  UCMD  (13/31)  suggesting  that 
COL6A1 are a major cause in both BM and UCMD. The 
high number of new mutations could also be related to a 
more extensive gene mutations search.
Consistent  with  previous  reports  (7),  most  dominant 
mutations in our cohort (12 of the 21) were splice site 
mutations of  which 4 involved intron 13 (33%) and 2 
intron 14 (14%). A missense mutation was only found in 
one case, in cis with a splice-site mutation and making 
more complex understanding the individual contribution 
to the resulting phenotype. This was made even more 
complex  if  one  considers  the  possibility  for  reduced 
penetrance  and  different  expressivity  seen  in  two 
families.  Seven  different  recessive  mutations  were 
identified,  and  4  were  deletions,  all  associated  with 
UCMD.
In  COL6A2 we  have  identified  6  causative  dominant 
mutations and 19 recessive mutations in 24 families. 
The relatively larger number of recessive compared to 
dominant  changes may be explained by the fact  that 
COL6A2 seems more associated with AR inheritance in 
UCMD patients (17). Consistently, our cases harbouring 
mutations  in  COL6A2  were  mainly  UCMD.  Alike 
previous  reports  (7),  most  dominant  mutations  in  our 
cohort  (5  of  the  6)  were  splice  site  substitution  and 
deletions (83%). 
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In  patients  with  recessive  inheritance,  10  were  novel 
deletions (52,6%), and  two were large deletions. 
To date, only 18 deletions in 255 mutations are recorded 
in Leiden mutation database, and our data contribute to 
enlarge  this  subgroup  of  variant further  corroborating 
the  importance  of  searching  for  deletions  when  
suspecting collagen related disorders. Interestingly,  the 
novel  c.2839_2850del/p.Leu947_Gly950del  recurred in 
four  unrelated  families  and  the 
c.1660_1668del/p.Lys554_Glu556del in two.  
In  COL6A3 we have identified 21 causative dominant 
mutations and 8 recessive mutations in 29 families. 
The relatively larger number of dominant changes could 
be related to the fact that the majority of patients (13/17) 
for  whom clinical  data were available were BM. Most 
dominant mutations in our cohort (9 of 21,  43%) were 
missense, similar to data present in mutation database 
(328/338  variants  detected  in  COL6A3  were 
substitution).  
COL6A3 dominant  mutations were widespread across 
the entire gene but apparently localized in the first part 
of the gene. 
Of  the  8  recessive  mutations  identified,  4  were 
missense  (50%)  and  the  c.7447A>G/  p.Lys2483Glu 
recurred in 3 unrelated families with muscle MRI pattern 
consistent with BM. 
COL6A3 recessive  mutations  are  widespread  across 
the entire gene but apparently localized in the second 
part of the gene. 
Altogether 67 of the 82 mutations detected in  COL6A 
genes were novel, 38 dominant, and 29 recessive. The 
high number of new mutation may reflect not only the 
methods used in our laboratories, but also the extensive 
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supportive investigations, including analysis of collagen 
VI in fibroblasts and muscle MRI imaging performed in 
our Centre to help in directing genetic investigations. In 
fact, the highly polymorphic nature of the COL6A genes 
makes  it  difficult  to  definitely  assign  pathogenicity  to 
some  variants,  especially  missense  outside  the 
triple-helix domains of the protein. 
This  report  highlights  the  difficulty  on  assigning 
genotype-phenotype  correlations  and  the  extensive 
research of gene mutations needs considering the not 
obvious linkage between a kind of inheritance and the 
phenotype.  This  awareness  represents  the  winning 
corps of our approach. 
LAMA2
The  exact  prevalence  of  MDC1A is  unknown.   The 
regional  prevalence  is  variable:  early-onset  LAMA2 
muscular dystrophy accounts for about 30% of the CMD 
cases in European countries, but only 6% in Japan (18). 
We have identified 81 causative recessive mutations in 
85 families, 32 of which novel. The relative low number 
of novel mutations detected could be ascribed at ample 
array of already described mutations (1495 reported in 
the  Leiden  mutation  database).  In  keeping  with  data 
reported in the Leiden mutation database, we identified 
34,5%  nonsense  substitutions  and  almost  25% 
splicesite substitutions. Our cohort also included 16/81 
(19,7%)  frameshift  deletions.  The  recurrent 
c.2049_2050delAG, was found in a total  of  12 alleles 
whereas  the  homozygous  Kenyan  founder  mutation, 
c.7881T>G,  associated  with  a  variable  clinical 
phenotype (10)  was  found  in  two  families  in 
heterozygous  state  and  in  one  in  homozygous  state. 
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The Italian founder  mutation c.2901C>A (19) was not 
detected. 
Mutations  were  distributed  throughout  the  gene; 
different  from  those  reported  in  the  Leiden  database 
where the largest  number of  mutations occur in  exon 
38. Although it was not a specific aim of our report, our 
findings suggest lack of significant genotype-phenotype 
correlations  and  variability  in  clinical  presentation  in 
merosin-deficient CMD.
FKRP
We  found  18 different  mutations  in  our  study,  13  of 
which (72%) were missense, as in the Leiden database. 
Among  those,  the  recurrent  c.826C>A/p.Leu276lle 
occurred in 17 unrelated families, although there was no 
obvious correlations between the nature of the mutation 
and the severity of the disease. 
According  to  previous  reports,  no  patients  harboured 
two FKRP null alleles suggesting that the complete lack 
of  FKRP  might  be  embryonically  lethal.  The  two 
nonsense mutations found in our cohort in two unrelated 
patients  were  in  compound  heterozygosity  with  the 
recurrent  missense  mutation.  Reviewing  the  clinical 
notes  of  5/6  patients  with  CMD and  not  carrying the 
c.826C>A/p.Leu276Ile  further  substantiate  the 
impression that this particular protects individual from a 
severe form of the disease. 
POMGNT1
Twenty-three  pathogenic  recessive  mutations  were 
found in 20 families 13 of  which novel and 10 (43,5%) 
missense. The recurrent variant c.1539+1G>A, in intron 
17, reported by Diesen et al (2004) (20) as a founder 
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mutation in the Finnish population was present in 4/23 
patients. The high number of novel mutation reported in 
our  cohort  contribute  to  enlarge  also  the  group  of 
micro/macro rearrangements and nonsense mutations, 
that  were mostly  located towards  the last  part  of  the 
coding region.
POMT1
Of the 12 different mutations identified in our study, 5 
(41,6%)  were  missense,  though  the  recurrent  variant 
c.1598G>C/p. Ala200Pro was found only once. Again, 
our analyses contribute to enlarge the relatively small 
number of deletions reported in this gene (so far about 
10% of total changes).
POMT2
We have identified 15 causative recessive mutations in 
12 families, 4 of which novel, and about 80% missense. 
The  recurrent  variant  c.1997A>G/p.  Tyr666Cys  was 
found in roughly one fourth of the cases. Variant were 
scattered in all  exon and intron; we can only found a 
mild prevalence for exon 21 (3/15-20%).
FKTN
In  FKTN we  identified  6  recessive  mutations  in  5 
families, 2 of which novel.  The recurrent c.1167dupA, 
was  heterozygous  in  two  families. Contrary  to  data 
reported  in  the  Leiden  database  where  insertion 
(359/577) are the prevalent mutations, we found several 
missese changes, including the c.920G>A/p.Arg307Gln 
already described in the Italian cohort (11).
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LARGE
A  single  patient  harboured 2 mutations,  including  a 
novel  duplication  in  exon  4  adding  to  the  list  of 
mutations in LARGE.
SEPN1
In  SEPN1 we  have  identified  32  causative  recessive 
mutations in 40 families 9 of which are novel. Of the 32 
different  mutations  identified  in  our  study,  15 (46,8%) 
were missense, 7 deletion, 4 splicesite, 3 duplication,  1 
insersion  and  2  nonsense.  The  recurrent  variant 
c.943G>A/p.  Gly315Ser  was  found  in  13  kindred. 
Among  novel  variants  the  c.1-11_81del92  mutation 
affected also the 5'UTR for the first time. 
Different  from previously  reported  cases,  where most 
variants  were  nonsense,  microdeletions  or  insertions 
leading  to  frameshift,  as  well  as splice-site  mutations 
predicting an aberrant pre-mRNA splicing, we found a 
high rate of missense mutations (15/32) not necessarily 
around or at the potential catalytic site located in exon 
10.
Conclusion
In summary, data presented in this study represents the 
largest series of CMD from a referring molecular genetic 
laboratory in  UK,  if  not  worldwide.  Our  data offer  the 
opportunity for several considerations:
collagen  VI-related  disorders  represent  the  most 
common  form  of  CMD  in  our  cohort,  accounting  for 
about  one  third  of  total.  Patients  with  MDC1A follow 
closely  behind  accounting  for  about  29%  whereas 
dystroglycanopathies  and  RSMD seem relatively  less 
common (roughly 25% and 14%, respectively).
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Among  dystroglycanopathies,  mutations  in  FKRP 
represents  the  most  common  and  are  associated 
particularly with a LGMD clinical presentation. Mutations 
in POMGNT1 , represent the second common aetiology.
There  seem  that  there  are  no  clear-cut 
genotype-phenotype correlations. It appears that neither 
clinical  presentation  can  predict  the  gene/mutation 
affected  nor  that  individual  genes  display  distinctive 
features to be used in clinical practice.  
The level of allelic heterogeneity is extremely high with 
a wide array of  novel  mutations being detected.  This 
implies  that  full  gene  testing  (eventually  adopting 
modern,  fully  automated  high-throughput 
methodologies)  are  needed  to  define  the  genetic 
breakdown of the CMD population. 
Finally, several data are in contrast with those reported 
in previous study concerning single series of patients, 
but  largely  agree  with  those  reported  in  general 
mutation database. This is a further significance of our 
large  cohort  that  correlates  well  not  only  with  the 
frequency regardless a particular geographic areas but 
also  the  frequency  of  CMD-LGMD  population 
worldwide. 
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 Chapter 3
Muscle MRI studies 
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1 Muscle MRI: what we learn by pattern 
recognition analysis
Until  recently  the  use of  muscle  magnetic  resonance 
imaging (MRI) in neuromuscular disorders was limited 
to inflammatory myopathies. Few systematic studies on 
muscle MRI in inherited neuromuscular disorders have 
been  published,  mostly  to  highlight  the  selectivity  of 
muscle  involvement  in  relation  to  other  diagnostic 
investigations  performed.  During  the  past  few  years, 
however,  there  has  been  increasing  evidence  that 
muscle  MRI,  in  combination  with  a  detailed  clinical 
assessment  and appropriate biochemical  studies,  can 
identify  specific  patterns  of  muscle  involvement  and 
help  in  the  differential  diagnosis  of  neuromuscular 
disorders  in  children  and  adults.  We  report  our 
experience on the clinical value of muscle MRI in the 
diagnosis  of  patients  with  inherited  muscle  disorders, 
with a focus on practical aspects related to establishing 
mutations pathogenicity or differential diagnosis.
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neuromuscular disorders
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Pisciotta  C.,  Fiorillo  Chiara,  Santoro  Lucio,  Bruno 
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Introduction
As  described  in  chapter  2  mutations  in  the  transient 
receptor potential vallinoid 4 (TRPV4) gene may cause 
diverse  autosomal  dominant  neuropathies  including 
hereditary  motor  and  sensory  neuropathy  type  2C 
(HMSN2C),  hereditary  motor  neuropathy  (HMN), 
scapulo-peroneal  spinal  muscular  atrophy  (SMA)  and 
congenital  distal  SMA  (1-3).  Genotype-phenotype 
correlation is not yet define and mutation in the same 
domain of the receptor could be determinate alternately 
distal SMA or CMT conditions (4). It is also described an 
intrafamilial variable penetrance (5). So in case of early 
genetic detection is too difficult make a judgment on the 
prognosis only on base on mutation. 
Patients and methods
We studied the pattern of muscle MRI in two patients 
with  congenital  distal  SMA (a 2-year-old  boy  and  an 
11-year-old  girl  —  showing  marked  weakness  in 
proximal and distal muscles, atrophy of distal legs and 
clubfoot  with an electromyography and muscle biopsy 
compatible  with  neurogenic  conditions)  and  in  one 
patient (a 63 years men) affected by CMT2C. The three 
patients  was  harbouring  three  different  mutation  in 
TRPV4 (p.P97R; p.R232C; p. R315W).
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Results and Discussion 
A similar pattern of muscle MRI  was evident  either in 
patients with congenital distal SMA than in patients with 
CMT2C with  a  predominant  alteration  of  anterior  calf 
muscle  (tibialis  and  peroneus  groups) with  relative 
sparing  of  medial  gastrocnemius.  Nevertheless,  in 
congenital  distal  SMA,  at  thigh  level  there  is  an 
extensive and widespread fatty atrophy, with selective 
spread of biceps femoris, semimtendinosus and vastus 
lateralis, fewer evident in CMT2C.  This finding suggest 
the presence of a specific and selective pattern with a 
continuum of  skeletal  muscle  involvement  in  the  legs 
between  phenotypes  in  TRPV4  gene-mutation-related 
skeletal  muscle  disorders.  The  predominant 
involvement  of  thigh’s  muscle in  distal  SMA could be 
helpful in distinguish this form in situation of overlap of 
clinical finding, helpful in make consideration on natural 
history. 
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Figure1
Transverse T1-weighted MRI of  thighs and calf  muscles in 
dSMA patients  harboring mutations in  TRPV4 (a-d)  and in 
CMT2C patient  (e-f).  An extensive fatty  atrophy preserving 
biceps  femoris  and  medial  gastrocnemious  is  evident  in 
dSMA and fewer, although also evident, in CMT2C patient. 
This  pattern  is  different  from  non-TRPV4  patients  i.e. 
DYNC1H1  patient presented in chapter 2 where the medial 
compartment at thighs – with hypertrophy of adductor longus 
– and anterior muscles at calf  level – tibialis anterior – are 
spared.
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Introduction
Congenital  myopathies  (CM)  due  to  mutations  in  the 
skeletal  muscle  ryanodine  receptor  gene  (RYR1)  are 
the most common forms of CM with an ever increasing 
array of mutations being associated with a wide set of 
clinical  syndromes,  including  central  core  disease 
(CCD),  susceptibility  to  malignant  hyperthermia, 
multi-minicore  disease  (MmD)  (1,  2),  centronuclear 
myopathies (3), 3-OH methylglutaconic aciduria (4) and 
core-rod  myopathies.  Both  autosomal  dominant  (AD) 
and autosomal recessive  (AR) patterns of  inheritance 
are  possible  regardless  of  the  underlying  clinical 
phenotype.  Heterogeneity  in  terms  of  clinical  and 
genetic findings is paramount. On one hand, there is a 
wide spectrum of clinical severity ranging from children 
who never achieve independent walking, to individuals 
with easy fatigue and fully-blown muscular atrophy, to 
patients  with  susceptibility  to  malignant  hyperthermia 
and little or no muscle weakness. On the other hand, 
muscle  biopsy,  the  gold  standard  for  a  definitive 
diagnosis of CM, often presents unspecific pathological 
findings  that  are  unable  per  se to  indicate  the 
responsible  genetic alteration.  Also,  allelic 
heterogeneity  does  not  allow  precise  locus-driven 
genotype-phenotype correlations.
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Multi-centre  experience  and  current  literature  suggest 
that muscle Magnetic Resonance Imaging (MRI) is able 
to recognize characteristic patterns of selective muscle 
involvement in many neuromuscular disorders, including 
those associated with mutations in RYR1 (5, 6, 7), and 
might help narrowing the differential diagnosis prior to 
muscle biopsy (8; 9), if not as an alternative to it.
We present  the case of  two sisters with clear clinical 
findings  of  CM  co-morbid  with  AR  cystinuria  type  B. 
Despite  a  slight  intra-familial  clinical  variability  and 
unremarkable muscle biopsy findings, the recognition of 
a  characteristic  muscle  pattern  on  MRI  allowed  the 
genetic  diagnosis  with  the  identification  of  a  new 
mutation in RYR1.
Case report
Two sisters (F.T. & F.A.),  coming from southern Italy, 
were  referred  to  the  Developmental  Neuroscience 
Department of IRCCS Stella Maris at the age of 13 and 
6 years respectively.
Both  were  born  at  term  by  cesarean  section  due  to 
breech  presentation,  to  healthy  consanguineous 
parents. Pregnancies had been remarkable for reduced 
fetal movements in both cases. Past medical history in 
the mother was significant, with one miscarriage in the 
first trimester of pregnancy and one stillbirth. 
Patient 1 (F.T.) is a 16 year-old girl who was floppy at 
birth  and  had  feeding  and  respiratory  difficulties  and 
delayed  development.  She  presented  at  birth  with 
bilateral clubfoot, congenital scoliosis and poor suction; 
she  is  able  to  walk  with  ortosis  since  age  6.  The 
younger sister (F.A.), now aged 6, had a similar though 
milder  clinical  phenotype:  she achieved  the  sitting 
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position at  13 months and independent  walking at  36 
months.
The  clinical  course  was  slowly  progressive  in  both 
children. Cardiac, respiratory and cognitive functions as 
well  as routine laboratory investigations (including CK 
levels) were all normal.
An  electromyography  (EMG)  of  the  lower  limbs  in 
patient  1  at  the  age of  5  years showed a  myopathic 
pattern.  Muscle  biopsy  indicated  marked  dystrophic 
changes without  any additional  features.  Interestingly, 
both girls also present with kidney stones and elevated 
urinary  levels  of  cysteine  with  childhood  onset.  A 
homozygous c.605-3C>A mutation in the SLC7A9 gene 
corroborated the clinical diagnosis of cystinuria type B. 
Parents  were  heterozygous  for  the  mutation,  which 
impairs the SLC7A9 gene splicing.
At first examination, F.T. and F.A. showed generalized 
hypotonia, myopathic facies with high arched palate and 
triangular  mouth.  Extra-ocular  muscles  were  spared. 
Deep tendon reflexes were diminished in both girls but 
there were neither amyotrophies nor pes cavus. In F.T. 
the latest neurological examination was significant for a 
prevalent  weakness  of  lower  limbs,  hyperlordosis, 
dorsal  and lumbar scoliosis  and joint  hyperlaxity.  She 
could  not  walk  without  orthesis.  F.A.  had prevalent 
weakness  at  scapular  girdle;  she  could  walk 
independently but with waddling gait and bilateral foot 
drops and she was unable to run. 
Neurophysiological examinations, including motor action 
potentials and nerve conduction studies, were normal in 
both girls. Muscle MRI  of  the thighs using 1.5 T  MR 
System (Signa Horizon LX, Healthcare GE, USA) and a 
conventional  T1 weighted spin eco images showed a 
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typical  pattern  of  RYR1  myopathy  with  the  selective 
involvement  of  vasti,  sartorius,  adductor  magnus  and 
the relative sparing of the rectus, gracilis and adductor 
longus (Figure 1a and 1c).  In addition,  within the calf 
muscle,  there  was  selective  involvement  of  soleus, 
gastrocnemii and peroneal group with relative sparing of 
the tibialis anterior (Figure 1b and 1d).
“Capillary” Sanger sequencing of the coding exons and 
flanking introns of RYR1 using the BigDye 3.1 chemistry 
uncovered  a  homozygous  c.14928C>T  mutation 
(p.F4976L)  in  patient  1.  The  mutation  was  also 
homozygous in her younger sister, heterozygous in the 
healthy  parents,  and it  was not  found in  500 healthy 
control chromosomes. Computational predictions using 
the  Polyphen-2  (genetics.bwh.harvard.edu/pph/)  and 
PMut  (mmb2.pcb.ub.es/pmut)  bioinformatic  tools 
suggested  that  the  new  p.F4976L  was  “probably 
damaging”.
Discussion 
The MRI pattern of  selective muscular  involvement  in 
patients  with  central  core  disease  due  to  RYR1 
mutations was initially reported in 2004 (5). The initial 
findings  have  been  subsequently  confirmed 
independently  in  patients  with  dominantly-inherited 
mutations (6) and, more recently (7), in a larger sample 
with different  degrees of  clinical  severity and different 
patterns  of  inheritance.  Mutations  in  RYR1 are 
associated with a wide range of phenotypes, including 
central  core  disease  (CCD),  malignant  hyperthermia 
susceptibility  and  distinct  subgroups  of  multi-minicore 
disease (MmD) (1, 2), centronuclear myopathy  (3) and 
core-rod myopathy  (4).  Because  of  the  impressive 
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overlap  of  clinical  and  pathological  findings  between 
different  CMs  and  of  the  ever  increasing  genetic 
heterogeneity, selection of the correct gene to analyse 
remains  a  difficult  task,  especially  in  the  absence  of 
cost-effective  functional  assays.  In  this  context,  the 
muscle MRI appears to be a useful “biomarker”, as use 
of this tool together with the correct result interpretation 
may allow an informed prioritization of gene analysis in 
several CMs.
Our  report  of  a  new  RYR1 mutation  discovered 
following suggestive MRI changes lends further support 
to this hypothesis, especially considering the unspecific 
muscular findings and the dissimilar clinical presentation 
in the two sisters. 
Although a recent report suggests that the spectrum of 
RYR1-related  myo-imaging  is  broader  than  originally 
reported  and  that  there  seems  to  be  a  gradient  of 
muscular  hypo-intensity  (7),  there  remain  sufficient 
distinctive  fundamental  features  which  turn  out  to  be 
crucial when clinical and pathological data cast doubts 
onto  performing  time-consuming  gene  analysis.  As 
suggested  by  others  (7),  detailed  examination  of 
involvement (or sparing) of selective muscular groups, 
such as the extra-ocular  muscles,  might  represent  an 
adjunctive  decisive  factor  prior  to  embarking  on  the 
testing of the large RYR1 gene. Likewise, it is appealing 
that  mutation  screening  of  RYR1,  which  is  highly 
polymorphic,  with  more  than  300  disease-related 
variants  and  a  similar  number  of  “possibly”  neutral 
changes  (Human  Gene  Mutation  Professional 
Database, www.hgmd.cf.ac.uk/; latest accession March 
2012),  would  benefit  of  a  relatively  less  costly 
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“functional”  MRI  investigation  to  substantiate  the 
predicted deleterious effect of novel sequence variants.
In conclusion, this study presents a novel RYR1 genetic 
variant  whose  pathogenic  significance  was  reinforced 
by a RYR1-specific pattern on muscle MRI. Muscle MRI 
is  an  important  diagnostic  tool,  particularly  for 
myopathies  associated  with  a  wide  phenotypic 
spectrum, such as those RYR1-related.
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Figure 1
                         
T1 weighted transverse scans performed through thigh and 
calf in F.T at 13 yrs (1a and 1b) and in F.A at 6 yrs (1c and 
1d).  Both  scans  show  the  selective  involvement of  vasti, 
sartorius,  adductor  magnus  and  relative  sparing  of rectus, 
gracilis  and  adductor  longus  (1a,  1c)  and  the  selective 
involvement of soleus, gastrocnemii and peroneal group and 
relative sparing of the tibialis anterior within the lower leg (1b, 
1d). 
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2 Expanding the use of muscle MRI: from 
overall pattern to pattern within muscle
 
The  assumptions  here  below  are  a  part  of  a 
collaboration project involving Dubowitz Neuromuscular 
Centre (London).  
2.1 Can muscle MRI help distinguish myopathic  
from neurogenic genetic causes of distal 
weakness?
by  Astrea  Guja,  Battini  Roberta,  Gunny  Roxana,  Manzur  
Adnan, Mercuri Eugenio, Morrow Jasper, Muntoni Francesco,  
Reilly Mary, Tarek Yousry
manuscript in preparation
Introduction
In the past decade there has been increasing evidence 
that  muscle  MRI  may  play  an  important  role  in 
identifying  genetically  different  conditions.  Specific 
patterns  of  muscle  involvement  in  series  of  patients, 
including primary myopathies or muscular dystrophies, 
have  been  consistently  outlined  demonstrating  that 
muscle MRI has the power to direct genetic tests in a 
number of neuromuscular conditions (1). 
On the other hand there has been limited focus on the 
role  of  muscle  MRI  in  distal  myopathies  and  spinal 
muscular  atrophies  (2)  and,  so  far,  no  studies  have 
specifically  compared the ability  of  MRI to distinguish 
myogenic and neuropathic disease processes.
Distal  myopathies  refer  to  inherited  or  sporadic 
disorders characterized by progressive weakness and 
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atrophy  beginning  in  hand  or  feet  muscles  and  by 
myopathic changes in skeletal muscle biopsies (3). The 
increasing  number  of  new  genetic  aetiologies  for 
neuromuscular disorders has permitted to identify novel 
forms  of  distal  spinal  muscular  atrophies,  including 
SMA-LED and TRPV4-related myopathies (4,5), though 
the associated myoimaging features were described in 
a limited number of patients (6), making difficult to draw 
clinically relevant correlations.  
In principle, the use of a muscle MRI study could be of 
interest in differential diagnosis of conditions presenting 
distal  muscle  weakness  and  atrophies  where  the 
primary muscular or neurogenic involvement is at times 
difficult on clinical and neurophysiological grounds alone 
and  in  the  presence  of  a  high  level  of  genetic 
heterogeneity.  Although  some  clues  such  as 
proximal-distal gradient or more marked involvement in 
myopathies than in peripheral neuropathies have been 
proposed,  they  have  not  systematically  confirmed  in 
large  scale  studies.  Moreover,  current  studies  mostly 
ignore  pattern  presentation  within  individual  muscles, 
though this seems very helpful also in these conditions, 
as in Bethlem myopathy (1). 
We  here  studied  muscle  MRI  images  in  a  group  of 
patients with a pattern of distal weakness and affected 
by  either  inherited  neurologic  conditions  of  anterior 
horns or distal myopathies. Our aims were: 
1)  to  verify  the  ability  of  myoimaging  in  specifically 
detecting the neurogenic or miopathic condition; 
2) to recognize in the two conditions possible distinctive 
characteristics; 
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3)  to  elucidate  the  mechanisms  underlying  muscle 
specific distribution of changes in different disorders.
Methods 
We reviewed muscle MRI scans performed in the last 
10 years at GOSH and Hammersmith Hospital (London, 
UK) and at the IRCCS Stella Maris (Pisa, Italy) obtained 
from patients included in a regular clinical follow up and 
consecutively seen at the three centres. 
Patients were included in the study group if they met the 
following criteria: i) presence of at least one muscle MRI 
scan of thigh and leg muscles performed at one center; 
ii)  absence  of  weakness  in  limb-girdle  muscles;  iii) 
available clinical vignette, neurophysiology data, levels 
of serum creatine kinase (CK), genetic information when 
available,  and,  eventually,  information from muscle or 
nerve biopsies. 
With  these  inclusion  criteria,  we  selected  MRI  scans 
from a total of 38 patients, including 
22  patients  with a  genetically  confirmed  myopathic 
disorder  or  with  a  genetic  condition  affecting  anterior 
horn  cell, and  not  related  to  the  common 
SMN1-associated form of SMA; 
16  patients  with  the  same  condition  but  not  yet 
genetically defined.
All MRI scans were performed according to the protocol 
previously used by our groups using conventional T-1 
weighted  spin  echo.  Non  contrast  transverse  images 
were obtained in the legs, selecting the axial plane with 
respect to the long axis of the body (7).
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This study was approved by the ethical committees of 
the  participating  Institutions  upon  receiving  patients’ 
written informed consent.
Image Analysis
All the scans collected were standardized in format and 
were reviewed blindly to genetic and clinical data by two 
expert  neurologists  (J.M.,  A.M.)  and  two 
neuroradiologists  (T.Y.,  R.G.).  We initially  designed  a 
validation arm of the study. Experts assessed data from 
12 patients with known genotype by obtaining a group 
full  consensus.  Seven  patients  presented  a 
molecularly-confirmed  myogenic  disease  (5  harbored 
mutations in MYH7, 1 in NEB and 1 in MYH2) and 5 a 
genetically  confirmed  neurogenic  disease  (4  had 
mutations in  DYNC1H1 and 1 in  DYNACTIN2). In this 
first part of the study, all the examiners were asked to 
provide expert impression of the gestalt of an image and 
a  visual  understanding  of,  based  on  the  following 
characteristics:  a)  quality  of  images;  b)  presence  of 
atrophy or hypertrophy of muscles bulks; c) quantitative 
degree  of  normal  or  abnormal  signal  intensity  within 
each  muscle  according  to  the  described  Mercuri 
gradient;  d)  possible  presence  of  a  distal  versus 
proximal gradient of muscle involvement; e) analysis of 
texture within each individual muscles.
Results  of  the  “gist  of  a  muscular  scene”  from each 
examiner  were  collected  in  a  score  sheet  and 
subsequently analyzed in order to find a marker capable 
to  distinguish  the  two  clinical  disease  categories 
(myopathies versus neuronopathies).
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A non-parametric test (Mann-Whitney test) was used to 
evaluate if any differences between muscle involvement 
were  evident  at  thigh  and  calf  level  in  each  groups. 
Significance was set at p <.05. The Wilcoxon test was 
used  to  correlate  differences  between  thigh  and  calf 
muscles in each group, independently. Significance was 
set at p<.05. 
Having completed this validation task, examiners were 
asked to apply the consensus scoring system blind to 
the final diagnosis to an additional set of images from 
26  patients  (5  each  genetically  confirmed neurogenic 
and  myopathic disorders, and 8 each yet molecularly 
undefined neurogenic and myopathic conditions).
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Results
Table 1 summarizes clinical and genetic data in our patients. 
Pts DOB Age at 
exam.
Gene Neurop. Bio. Clinical 
finding
A/NA
C.L. 04/03/1992 15y DYNC1H1 N M Arthrogryp.
predominant 
lower limb 
weakness 
with thinning 
of lower legs 
A
B.S. 06/11/1972 38y DYNC1H1 N N Very mild 
distal 
weakness
A
J.A. 26/02/1999 8y3m DYNACTIN2 N M Scapular, 
peroneal and 
hip girdle 
weakness
A
B.T. 23/12/2000 10y3m DYNC1H1 M M Predominant 
lower limb 
weakness 
with thinning 
of lower legs
A
J.J. 12/01/1988 11y2m DYNC1H1 M NP Marked 
distal 
muscular 
atrophy and 
weakness
A
M.L. 24/11/1993 16y9m MYH7 M NP Mild 
scapulo-pero
neal 
weakness
A
B.A. 08/06/1992 15y MYH7 M D Mild 
scapulo-pero
neal 
weakness
A
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F.A. 13/11/1995 15y6m MYH7 M M Pes cavus, 
mild distal 
weakness
A
P.V. 03/03/2001 8y6m MYH2 M M Mild 
scapulo-pero
neal 
weakness
A
H.N. 20/12/2002 6y6m NEB M M Severe distal 
weaknes, 
bilateral foot 
drop
A
M.C. 02/03/1958 42y MYH7 N M Mild 
scapulo-pero
neal 
weakness
A
J.M 13/07/1996 16y MYH7 N NP Predominant 
lower limb 
weakness 
with thinning 
of lower legs
A
T.G. 30/11/1999 10y6m TRPV4 N N Arthrogr. 
predominant 
lower limb 
weakness 
NA
P.R. 22/02/1988 19y BAG3 M NP Severe 
weakness of 
lower limbs 
with 
foot-drop.
A
H.L. 15/06/1994 5y8m BICD2 N NP Mild 
scapulo-pero
neal 
weakness
A
H.P. 04/07/1962 39y3m BICD2 M M Mild 
scapulo-pero
neal 
weakness
A
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V.I. 08/10/2001 8y9m BICD2 N M Arthrogryp.
reduced 
muscle bulk 
in lower 
limbs more 
marked 
distally
NA
W.J. 16/05/1997 12y2m BAG3 N M Longstandin
g weakness 
of lower 
limbs with 
foot-drop
A
S.K. 28/12/1995 15y1m BAG3 N M Bilateral pes 
cavus and 
tiptoe 
walking very 
minimal 
distal hand 
weakness
A
McC 01/10/1989 12y TPM3 normal M Mild distal 
myopathy
A
B.S. 27/02/2002 3y5m DYNC1H1 N N Arthrogryp. A
S.C. 27/09/1977 23y NEB M M Distal 
myopathy 
with 
footdrop
A
P.D. 25/07/1985 17y2m N nor
mal
Arthrogryp.
reduced 
muscle bulk 
in lower 
limbs more 
marked 
distally
C.M. 13/08/2007 2y6m N NP Congenital 
talipes 
muscle bulk 
reduced
A
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S.A. 20/10/2003 7y5m N N Arthrogryp. 
reduced 
muscle bulk 
in calves but 
A
P.J. 24/11/2011 14y11
m
M M Mild distal 
weakness
A
B.G. 03/03/2001 10y10
m
M M Mild distal 
weakness
A
M.R. 15/01/2000 10y9m N N Distal 
myopathy 
with 
footdrop, 
congenital 
talipes 
equinovarus 
bilaterally
A
W.A. 07/06/1965 41y 2m N NP Distal 
myopathy 
with 
footdrop
A
C.S. 25/02/2000 10y6m NP D Marked 
distal 
weakness
A
R.K. 19/09/1965 36y5m M M Marked 
distal 
weakness
A
B.F. 20/07/1994 14y M M Distal 
myopathy 
with 
footdrop
A
M.D. 11/01/1997 13y4m M M Scapular, 
peroneal  
weakness 
A
R.S. 03/01/2004 4y6m M M Distal 
myopathy; 
footdrop
A
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T.C. 20/03/1993 17y N M Distal 
myopathy 
with 
footdrop
A
D.A. 18/12/1989 9y8m N D Arthrogryp. 
very severe 
distal 
involvement 
in the limbs
A
L.E. 07/04/1988 14y4m N D Arthrogryp.
mild 
weakness in 
the lower 
limbs 
A
W.An 17/12/1987 11y3m N NP Mild 
weakness in 
the lower 
limbs
A
Age at exam.: age at examination; DOB: date of birth; 
Neurop.: neurophysiology; Bio.: biopsy; N: neurogenic; M: 
myopathic; NP: not performed; D: dystrophic; A: ambulant; 
NA: non-ambulant; Arthrogryp.: Arthrogryposis.
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Data analysis in the validation study
a. Image quality
All  images,  except  one,  had  a  good  quality:  at  thigh 
level 7/12 images scored 0 (“no artifacts”) whereas the 
remaining  scored  1  (“presence  of  artifacts,  but  all 
muscles were gradable”). At the level of the calves 9/12 
scored 0, 2/12 scored 1 and only 1/12 had a score of 3 
(“strong  artifacts  in  several  muscles,  cannot  be 
analyzed”).  The  latter  image  was  not  included  in 
statistical analysis.
b. Muscles bulks
For  what  concern  muscles  bulk  at  thigh  level, 
neurogenic  conditions  showed  normal  bulk  (2/5)  or 
hypotrophy/hypertrophy  (3/5),  whereas  myopathic 
conditions  consistently  were  either  normal  (n=  3)  or 
hypotrophic (n= 4). There were no differences between 
anterior  or  posterior  compartments  except  for 
hypertrophy of adductor longus in neurogenic condition 
(3/5)  that seems to be a prevalent  feature in  most of 
them and not evident in myopathic conditions (0/7). 
At the level of calves, both neurogenic and myopathic 
disorders  had most  of  muscles  bulks  in  the  range of 
hypotrophy (3/5 and 4/7, respectively), regardless of the 
involved  compartment.  The  bulk  in  the  remaining 
muscles  were  in  the  normal  range.  No  muscle 
hypertrophy was evident at this level.
c. Appraising the values of Mercuri gradient 
From  a  descriptive  point  of  view,  several  muscles 
analyzed in neurogenic conditions were in the range of 
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high Mercuri score (score 4), in particular, at thigh level 
(49/120  muscles  at  thighs  and  25/70  at  calves). 
Conversely, no muscles (both at thigh and calf) had a 
score as 4 in myopathic conditions, with most of them 
presenting a score of 3 at the level of tibialis anterior, 
extensor  digitorum longus  (EDL)  and  soleus.  From a 
statistical  point  of  view,  median  score  values  were 
higher  in  the  group  of  neurogenic  conditions  than  in 
myopathic disorders but for the adductor longus muscle 
where scores were similar and EDL where scores were 
higher  in  myopathic  conditions,  although  with  a  large 
variation. 
Median value difference between the two groups was 
significance  both  at  thigh  (p<.005)  and  at  calf  level 
(p.<018) (Table 2).
Moreover, we could detect at thigh level in neurogenic 
conditions  only  a  prevalent  involvement  of  anterior 
respect to posterior compartment, with a relative sparing 
of  adductor  longus.  There was a significant  prevalent 
involvement  in  all  anterior  muscles  in  neurogenic 
diseases  (vastus  intermidius  p<.01;  vastus  lateralis 
p<.003;  vastus medialis  p<.018).  Muscles in  posterior 
compartment  were  not  significantly  different  between 
the two clinical condition with the important exception of 
the capus longus of bicepes femoris (p<.018). In medial 
compartment,  we  observed  a  significant  difference  in 
fewer  specific  muscles:  gracilis  (p<0.1),  sartorius 
(p<.005)  and,  marginally,  right  adductor  magnus 
(p<.048).  At calf level differences could be find only in 
the posterior  compartment (in  particular  in  lateral  and 
medial  gastrocnemius  p<.003),  whereas  the  anterior 
compartment was predominantly involved in myopathic 
conditions. 
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Table 2 Median value difference between neurogenic and 
myopathic conditions
Conditions Thigh Calf Significance
Median Interquar. 
range
Median Interquar. 
range
Neurogenic 5 2,75 4,5 2,25 P<.005
Myopathic 1 1 2 2 P<.018
d. Presence of a  disto-proximal gradient  
A  prevalent  calf  involvement  could  be  detected  in 
myopathic conditions as highlighted by the analysis of 
Mercuri gradient (see above) though this did not reach 
statistical  power  (p<.066).  Four  out  of  7  myopathic 
patients  had  distal  more  than  proximal  high  median 
scores,  with  the  remaining  3  cases  having  similar 
values.  There  was  no  significant  differences  in 
neurogenic  conditions  (p=  0.85)  with  median  score 
values  proximally  higher  in  3  cases  and  more 
pronounced distally in 2. 
e.  Qualitative analysis in individual muscles  
Considering  texture  pattern,  experts  occasionally 
identified  an  alteration  that  was  termed  “islands”  in 
those muscles completely replaced by fat infiltration but 
with  evident  sparing  of  a  little  parts  of  muscle  bulks. 
This alteration was evident in 5/5 neurogenic conditions 
but in 0/7 myopathic conditions (Figure 1).
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Data  analysis  in  an  additional  set  of  26 
unknown patients
A blind review of muscle MRI scans from an additional 
set of 26 patients adopting the above mentioned criteria 
and  evaluations  gave  a  high  inter-  and  intra-rater 
sensitivity and specificity (95%).  
Figure  1.  Muscle  MRI  at  thigh  and  calf  level  in  two 
neurogenic  conditions  (DYNC1H1  and  BICD2)  and  in  one 
myopathic  condition  (MYH7).  Note  the  islands  in  the 
neurogenics ones (red circle).
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Discussion
The  rationale  of  this  study  was  to  evaluate  the 
sensitivity  and  specificity  of  a  visual  inspection  of 
muscle MRI scans to identify clues useful to differentiate 
distal neurogenic from distal myopathic disease. 
Our  results  suggest  that  muscle  MRI  could  be  a 
powerful predictor of neurogenic involvement in patients 
with a pattern of distal weakness. 
Some clues  could  be represented   by  the  degree  of 
muscles  involvement  that  appear  disproportionally 
higher  compared  to  the  clinical  functioning,  and  the 
predominant  involvement  at  thighs  in  contrast  to  the 
distal symptoms and signs. At calf level, the prevalent 
involvement  of  anterior  compartment  in  myopathic 
conditions compared to those observed in neurogenic 
diseases  could  be  another  important  discriminating 
factors,  as  well  as  the  disto-proximal  gradient  of 
involvement, evident in myopathic conditions but no in 
neurogenic ones. It  should be noted that no analyses 
from  patients  presenting  peripheral  neuropathies  (i.e. 
CMT syndromes) were included in the study. However, 
in this conditions differential  diagnosis could be made 
by  nerve  conduction  studies  that  are  unequivocally 
altered in CMT and normal in myopathic conditions.    
Another  clue  factor  could  be  the  relative  hypertrophy 
seen in neurogenic conditions (adductor longus in 3/5 
cases), since in none myopathic disorders increases of 
muscle bulks was evident, but it is also possible that this 
relates to the specific gene defects.
Finally the pattern of involvement within muscles seems 
to be the most  discriminating  factor.  The presence of 
«islands»  preserving  muscle  bulks  in  a  sea  of  fatty 
transformation was noted serendipitously but it appears 
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to be a red flag for neurogenic conditions, regardless of 
the genetic defect. 
The pattern of involvement within muscles, that is not 
something  normally  captured  by  Mercuri  grading  or 
reported in the literature to date, seems to be the most 
intriguing factor, and a useful  diagnostic marker of late 
neurogenic change in this clinical group. It is tempting to 
hypothesize  that the presence of islands in neurogenic 
conditions  could represent  the  effects  of  giant  motor 
units of the few remaining axons, but this impression will 
require more detailed investigation. Also, larger studies 
are needed to define island as a strong marker of distal 
neurogenic  disorders  and  useful  clues in  determining 
the severity of the disease.   
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Chapter 4
The Brain involvement
131
1 The brain involvement in DMD patients  
This section reports a neuropshycological study carried 
out in Duchenne Muscular Dystrophy patients so as to 
verify  the  presence  and  characteristics  of  literacy 
deficits  in  DMD, analyse  neuropsychological  profiles 
associated  with  reading  and  spelling  abilities  and 
compare  them  with  patients  with  Developmental 
Dyslexia (DD) ones. 
   
1.1.  Duchenne  Muscular  Dystrophy  and  
Developmental  Dyslexia:  comparison  of 
reading and neuropsychological profile
by  Guja Astrea,  Chiara Pecini,  Filippo Gasperini, Giacomo  
Brisca,  Marianna  Scutifero,  Claudio  Bruno,  Filippo  Maria  
Santorelli, Giovanni Cioni, Luisa Politano, Annamaria Chilosi,  
Roberta Battini.
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Introduction 
Duchenne muscular  dystrophy (DMD) is  a hereditary, 
X-linked  recessive  disorder  affecting  about  1  in  3500 
males  and  clinically  characterized  by  severe, 
progressive and irreversible loss of muscular functioning 
and strength (1). Brain involvement in DMD has been 
known  since  its  original  description  (2),  and  a 
meta-analysis  in  1,146  patients  has  showed  that 
full-scale intelligence quotients were at more than one 
standard  deviation  (SD)  below  the  mean  of 
age-matched  population,  although  frequency  and 
distribution did not seem to differ significantly (3). As a 
result of this downward shift, 35% of DMD children had 
full-scale intelligence quotient of less than 70, that is, in 
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the  “mental  retardation”  range  and  only  roughly  5% 
were above normal average (3). 
Notably, a significantly lower verbal intelligence quotient 
(VIQ) than performance intelligence quotient (PIQ) has 
been  reported  in  DMD  boys  (3),  in  addition  to  an 
increased  incidence  of  learning  disabilities  with  major 
difficulties in literacy skills (4,5,6,7). However, problems 
in reading and writing are still largely uncharacterized. 
When  reading  skills  in  DMD  were  studied  (7), 
impairments  have  been  reported  similar  to  those 
observed  in  children  diagnosed  with  Developmental 
Dyslexia (DD), a condition characterized by a significant 
deficit in reading decoding skills with normal non-verbal 
cognitive  abilities.  In  particular,  Billard  (1992)  (8)  has 
reported that  12 out  of  24  DMD children  had  severe 
reading disabilities compared to a similar size group of 
children affected by different  neuromuscular  disorders 
(i.e., spinal muscular atrophy).
Research of reading deficits in DD have suggested that 
multiple  neuropsychological  factors  may  partially 
account  for  defects  such as:  phonological  processing 
deficits  (9,10,11);  abnormalities  in  rapid  access  to 
long-term  phonological  representations,  specifically 
from  visual  input  (12);  sluggish  focused  multimodal 
attention  (13)  or  general  automatization  deficits  (14). 
We have shown that  phonological processing  deficits 
characterized only one subgroup of DD subjects with a 
history of early language delay, whereas speed deficit in 
rapid automatized naming tasks (RAN) can be observed 
also in children without  any history of language delay. 
This  finding  has  suggested  that  a  reduced  speed  in 
forming  visuo-verbal  associations  could  be  the  main 
cognitive  marker  of  DD  in  a  shallow  orthography 
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language such as Italian (15,16,17,18). Keeping in mind 
the characterization of DD children, we reasoned that a 
detailed  characterization  of  learning  skills  in  DMD 
children and a direct comparison of both disorders in a 
similar experimental setting could help better define the 
type and extent of learning difficulties in DMD. Thus, the 
aims of our study were two-fold: i) to verify the presence 
and  the  nature  of  literacy  deficits  in  DMD,  and  ii)  to 
analyse the neuropsychological profiles associated with 
reading  abilities  in  individuals  when  compared  with 
different groups of DD children. 
Patients and methods 
We recruited 36 subjects older than 8 years of age in 
order to ensure acquisition of basic scholastic skills. 12 
ambulatory  DMD  boys  (mean  age  at  examination  9 
years and 10 months) and 24 DD males (mean age 10 
years) were selected. Diagnosis for DMD children was 
based  on  onset  of  progressive  weakness  before  5 
years,  elevated  serum creatine  kinase  levels  (25-30x 
the normal  limits),  and confirmed by  either  molecular 
analysis  of  DMD  gene  or  by  significantly  reduced 
expression  of  dystrophin  in  sarcolemma  in  muscle 
biopsy,  or  by  both.  All  children  lived  at  home,  spoke 
Italian  as  a  primary  language  and  were  willing  to 
participate in the study. Additional inclusion criteria for 
participation  were:  i)  general  intelligence  level  within 
normal values (that is, within 1 standard deviation (SD) 
from the mean for their specific age group as assessed 
by Raven Colored Progressive Matrices’ score); ii) good 
physical health (a part from impairment related to DMD); 
and iii) regular school attendance.
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As a control group for reading disabilities, we selected 
24 DD children who met the following criteria: i) general 
intelligence level within normal limits (defined as stated 
above);  ii)  impaired  performance  on  standardized 
reading tests (a score two or more standard deviations 
below the mean of the normative sample on at least one 
of three reading decoding skill tests); iii) regular school 
attendance; iv) absence of adverse conditions in pre-, 
peri-, and post-natal clinical history and v) absence of 
neurological  abnormalities  established  from  a 
standardized neurological examination.  According to a 
semi-structured interview, DD children were divided into 
two  12-subject  groups,  depending  on  a  documented 
presence  of  Language  Delay  (LDD)  or  absence 
(noLDD). Children were labeled LDD if they manifested 
at  least  one  of  the  following  characteristics:  i)  no 
vocabulary burst before 24 months; ii) late (after age 30 
months)  combinatory  use  of  words;  iii)  persistent 
grammatically incomplete sentences after 4 years; and 
iv)  persistent  phonological  mispronunciations  after  4 
years (16).
All  children  underwent  a  battery  of  literacy  and 
neuropsychological  tests  validated  in  a  previous 
analysis  of  a  DD  population  (15,18)  (see  supportive 
information).  Data  were  collected  by  some  authors 
(F.G.,  C.P.,  G.A.)  at  the  IRCCS  Stella  Maris  from 
January  2010  to  November  2012;  all  subjects  were 
individually assessed in a quiet room, for 4 to 8 hours, 
sometimes spread over two days.  Subjects were given 
breaks if required. 
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Statistical analyses
Scores  were  considered  mildly  impaired  if  they  fell 
between 1-1.5 SD below mean; a performance of 2 SD 
below mean of  normal  values  was scored as a clear 
impairment.
One-way and Mixed ANOVAs were used to investigate 
literacy  and  cognitive  profiles  of  DMD  group  and 
differences  between  groups  on  various  literacy  and 
neuropsychological  tests.  Significance  was  set  at 
p<0.05 with Bonferroni post-hoc comparisons. 
Correlation analyses were conducted by the Spearman 
test in order to evaluate the association between literacy 
skills  and  verbal  and  non-verbal  neuropsychological 
abilities (significance at p<0.05).
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Results 
Table 1 summarizes clinical characteristics of DMD and DD 
patients and genetic features of DMD subjects included.
Case DMD NoLDD LDD
Age Schooling DYS
mutations
Age Schoolin
g
Age Schooling
1 7y 2 p.m. 7y11m 2 7y 2
2 8y 3 Del 45-50 8y 5m 3 8y 3
3 8y 3 p.m 9y 1m 3 8y 3
4 8y 3 Del 46-47 8y 5m 3 8y 3
5 8y 3 Del 48-52 8y 4m 3 9y 3
6 9y 4 p.m. 9y 5m 4 9y 4
7 10y 5 Del 51-55 10y 11m 5 10y 5
8 10y 5 Del 45-50 10y 9m 5 10y 5
9 10y 5 Del 45-47 10y 9m 5 10y 5
10 10y 6 Del 51-52 11y 4m 6 12y 6
11 11y 6 Del 46-47 12y 1m 6 12y 6
12 11y 6 Del 49-52 12y 1m 6 11y 6
DMD:  Duchenne  Muscular  Dystrophy; noLDD: 
Developmental  Dislexia  without  language  delay; LDD: 
Developmental  Dislexia  with  language  delay; DYS: 
Dystrophin; DEL: deletion; p.m.: point mutation.
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Intelligence Profile
Mean  Raven  Coloured  Progressive  Matrices’  score 
(CPM)  was  within  normal  in  DMD  group  (z  =  -0.51, 
SD=1.20) and did not significantly differ (F (2.32) = 1.98, 
ns) from that of DD groups (z = 0.15, SD= 0.87 for LDD; 
z = 0.22, SD=0.84 for noLDD).
In the DMD group, mean Full Scale IQ at WISC-III was 
within  borderline  range  (79.7,  SD  =15.9)  but  with  a 
slight  difference  between  performance  and  verbal 
quotients.  Mean  Performance  IQ  was  within  normal 
limits (PIQ=85.1) while Verbal IQ fell to within borderline 
range  (VIQ= 78.8;  F=8.56,  p<.05).  When considering 
each  subtest,  Information,  Arithmetical  Reasoning, 
Comprehension and Coding had the lowest mean group 
score (1SD below the population  mean).  The highest 
scores  were  observed  for  Figure  Completion,  Picture 
Arrangement and Block Design.
Reading and writing profile of DMD group
Individual  scores  as  well  as  means  and  standard 
deviations for different literacy skills in DMD children are 
reported in Table 2.
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Table  2.  Individual scores  and  means  and  standard 
deviations  (SD)  for  reading  and  writing  skills  in  the  DMD 
group.
Case Reading speed Reading accuracy Text
Comp
Writing
W NW Text W NW Text W NW
1 0.23 - -0.26 -5.50 -3.90 -2.05 -2.89
2 -5.21 -2.37 -0.33 -1.14 -3.00 0.23 0.48   -
3 0.18 -1.00 -0.94 -0.50 -0.20 0.26 0.06 -1.50 1.00
4 0.69 0.64 0.46 -0.50 0.20 -0.72 -1.15 -1.50 -0.33
5 -2.98 -1.33 -1.70 -4.25 -1.20 -2.62 -0.90 -5.50 -0.67
6 1.03 0.18 0.81 -0.67 0.00 0.40 -0.42 0.00 0.00
7 0.28 0.08 0.04 -0.86 0.02 0.90 0.10 0.21 1.37
8 0.33 0.62 0.00 1.00 0.25 -0.03 -0.50 0.00 1.00
9 -0.74 -0.38 0.98 -0.33 -0.50 0.31 -0.73 0.00 -0.67
10 -3.65 -3.25 -1.60 -0.97 -0.74 -0.34 -1.10 -0.85 0.73
11 -2.24 -1.75 -1.69 -0.89 0.55 -1.41 0.46 -2.70 -0.31
12 0.24 0.30 0.19 -0.22 0.27 -0.10 -1.27 1.00 0.00
 Mean -0.99 -0.73 -0.34 -1.20 -0.43 -0.58 -0.58 -1.25 0.21
SD 2.02 1.29 0.95 1.83 0.98 1.41 0.74 1.87 0.75
W: words; NW: non words; Text comp: text comprehension. 
Most cases presented a mild-to-clear impairment in at 
least  one  literacy  measure  and  only  4  subjects 
(individuals 6, 7, 8, and 9) had average values.
On  a  group  level,  all  literacy  measures,  with  the 
exception  of  non-word  spelling,  were  below  the 
population  mean but  only  reading accuracy for  words 
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and  spelling  for  words  fell  below  1SD.  Repeated 
ANOVA on word decoding (accuracy and speed), word 
spelling and reading comprehension did not show any 
significant differences among these measures (F (3.30) 
= 0.80, ns).
Comparison of  reading and writing difficulties 
between DMD and DD groups
Means and standard deviations of z scores obtained in 
literacy measures of DMD, LDD and noLDD groups are 
reported in Figure 1. 
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From a  descriptive  point  of  view,  all  groups  had  the 
worst  scores  in  word  reading,  reading  speed  and 
accuracy, and in word spelling. 
A  two-way  ANOVA,  with  group  as  unrepeated  factor 
and  literacy  measure  as  repeated  factor, revealed  a 
significant effect of the group (F (2. 27) = 7.3, p.<0.005) 
and an interaction between literacy measure and group 
(F  (3.81)  =  2.47,  p.<0.05).  DMD  children  performed 
better than LDD in all literacy measures whereas they 
did worse than noLDD in text comprehension, though a 
post-hoc analysis revealed that these differences were 
not significant.
Neuropsychological  profile  of  DMD  and  DD 
groups
Means and standard deviations of z scores obtained in 
verbal neuropsychological measures of DMD, LDD and 
noLDD groups are reported in Figure 2. 
There  was  a  clear  speed  deficit  in  all  three  Rapid 
Automatized Naming tasks (RAN tests) in DMD boys, 
each  performed  about  2SD  below  normal.  On  an 
individual  level,  58-66%  of  subjects  appeared  to  be 
severely compromised (< -2SD) depending on the type 
of  stimuli  (figures,  numbers and colours).  On a group 
level,  a  mild  impairment  was  also  found  in  semantic 
fluency  and  in  short  term  memory  (in  particular  in 
repeating quadrisillabic words).
Statistical  analyses  comparing  the neurophsycological 
profile in verbal domain (RAN, Working Memory, Verbal 
Fluency, Digit Span) of DMD to both DD groups showed 
a significant  measure effect (F (5.90) =6.9, p<0,0001) 
whereas effect  of  group (F (2.18)  =0.25,  ns)  and the 
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group by measure interaction (F (10.90) =0.92, ns) were 
not  significant.  All  subjects  in  the  three  groups 
presented a clear RAN speed deficit.
Means and standard deviations of z scores obtained in 
the non-verbal  neuropsychological  measures of  DMD, 
LDD and noLDD groups are reported in Figure 3. 
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The  group  of  DMD  boys  scored  slightly  below 
population mean on all non-verbal measures in speed 
visual  scanning  (barrage  tests)  and  in  visuo-motor 
integration  tasks  (VMI)  with  the  worst  performance 
being in  visual  memory (Corsi  test).  Comparing DMD 
and  DD  revealed  that  visual-scanning  skills  were 
143
predominantly impaired in DD subjects, VMI was within 
normal  limits  in  all  groups,  and  there  was  a  slight 
weakness in Corsi test for DMD individuals.
A Mixed Anova was conducted to compare DMD group 
to both DD groups in the non-verbal domain (Barrage, 
VMI, Corsi test). Measure (F (3.54) =0.78, ns), group (F 
(2.18) =0.04, ns) and group by measure interaction (F 
(6.54)  =0.93,  ns)  did  not  show  any  significant 
differences.
Neuropsychological  measures  correlated  to 
reading and writing skills 
Results from correlation analyses were similar between 
DMD and DD groups when analyzed together.  In  the 
DMD  group,  RAN  speed  was  the  only  measure 
significantly associated with reading decoding speed (rs 
ranging from 0.61 to 0.65) and accuracy (rs ranging from 
0.60  to  0.78).  For  text  reading  decoding  accuracy, 
however,  other  significant  concurrent  predictors  were 
found: PIQ (rs =0 .73) and visual scanning speed (rs from 
0.79 to 0.82).  Spelling  was correlated to phonological 
memory  measures  (rs  from  0.67  to  0.68).   These 
measures did  not  vary significantly  for  the DD group, 
where RAN speed (rs  from 0.53 to 0.61), together with 
phonological  processing  measures  (rs  from  0.51  to 
0.88),  and  visuo-spatial  tasks  (rs  from  .48  to  .64) 
predicted  reading  decoding  speed.  Reading  decoding 
accuracy was correlated to RAN speed (rs from 0.43 to 
0.50) and phonological processing (rs  = 0.53). Results 
were also similar for spelling measures with RAN speed 
and  phonological  processing  variables  as  concurrent 
predictors (rs from 0.55 to 0.84).
144
Discussion
This  study  was  designed  to  verify  the  presence  and 
characteristics of literacy deficits in DMD children and 
analyse the neuropsychological profiles associated with 
reading abilities when compared to similarly aged DD 
children. DD individuals with and without a documented 
history  of  language  delay  were  included  because 
delayed  verbal  communications  are  associated  with 
different cognitive and neurofunctional profiles (16,18).
Our  DMD  sample  had  non-verbal  intelligence  within 
lower  limits  of  normal  range  and  verbal  intelligence 
within  borderline  range,  although  motor  impairment 
typical  of  DMD  was  expected  to  interfere  with 
non-verbal  tasks.  This  profile  is  in  agreement  with 
earlier  data  reported  by  others  (3)  and  closely 
resembles  the  patterns  seen  in  DD  children  (19). 
Analysis  of  subtests  through  Wisc-III  revealed  the 
lowest  performances  in  tasks  involving  arithmetic, 
verbal comprehension and processing speed although 
large inter-subject variability was noted. This profile is 
also  in  agreement  with  previous  studies  (7)  and 
suggests that school-age DMD children have  greater 
difficulties  in  maintaining  and  processing  on-line 
information.
Given  a  normal  non-verbal  intelligence,  a 
comprehensive evaluation of reading, spelling and text 
comprehension  showed  relevant  weaknesses  in  all 
these  abilities.  The  incidence  of  reading  and  spelling 
difficulties  in  DMD group was about  30% higher  than 
expected value in the normal population. Nevertheless, 
a high inter-subject variability characterized the sample 
with 8  individuals being clearly deficient in more than 
one  domain  and  four  scoring  better  than  normal 
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similarly  age children.  These  results  confirm previous 
data documenting the existence of literacy difficulties in 
DMD regardless  of  the  presence of  a  clear  cognitive 
impairment (7). Furthermore, our study adds evidence 
to the notion that learning difficulties in DMD individuals 
tend  to  be  specific  though  not  single-domain,  as  the 
impairment  may  affect  both  reading  (speed  or 
accuracy), writing and text comprehension. Considering 
that  literacy  difficulties  found in  DMD resemble those 
documented in DD children, we reasoned that only the 
direct  comparison between children affected  by these 
two disorders could clarify the possible cognitive causes 
of their impaired reading abilities. Although DMD scored 
better  than the two DD groups, DMD and DD groups 
shared the worst performances in reading decoding and 
spelling.  Moreover,  the  presence  of  a  greater 
impairment in accuracy rather than in speed of decoding 
words and text,  creates a DMD profile  very similar  to 
that described in LDD subjects (15,16). 
The  profile  previously  described  could  result  from a 
compromised sublexical strategy of reading and from a 
deficit  in  phonological  processing.  DMD  were  clearly 
deficient in all RAN tests and had  mild impairment in 
some  measures  of  phonological  and  visuo-spatial 
processing. As in previous studies (15) and in our own 
sample, RAN deficit  is a common feature in LDD and 
noLDD,  and  is   closely  linked  to  reading  decoding 
deficits.  In  particular,  it  has  been  repeatedly 
hypothesised that   difficulty  in  rapid access of  lexical 
information from visual input can explain the deficit  in 
reading speed. This finding sheds new light on literacy 
difficulties  in  DMD  suggesting  that  besides   mild 
impairment  at  the  behavioural  level,  DMD  is  also 
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characterized by a clear cognitive deficit accounting for 
reading decoding difficulties. This hypothesis is further 
supported by correlation analysis highlighting a strong 
relationship  between  rapid  access  to  lexicon  and 
reading decoding both in DMD and DD males. It should 
be pointed out that RAN is a complex task presumably 
involving  visual  search  processes,  quick  and 
automatized  retrieval  of  phonologic  codes  from 
long-term  storage,  and  precisely  timed  integration 
between visual and lexical codes and it is quite difficult 
to  determine which  components  of  the RAN task are 
critically involved in reading impairment (20,21,22).
Another  fact  emerging  from  our  study is  that  DMD 
patients  share  with  LDD  only  a  mild  impairment  in 
phonological  processing  tasks  requiring  temporary 
storage  and  on  line  elaboration  of  phonological 
information.  Thus,  insufficiently  stabilized phonological 
representations  can  also  contribute  to  difficulties  in 
decoding accuracy. 
Finally, we also observed in DMD low performances in 
visual  tasks  requiring  visuo-spatial  elaboration  while 
visual scanning procedures are mostly preserved. This 
impairment might be an additional contributor to explain 
literacy difficulties. 
In summary, this study shows that  a multi-component 
cognitive  deficit  may  contribute  to  specific  literacy 
difficulties  in  DMD  with  rapid  access  to  lexicon  and 
phonological  processing being the core deficits in our 
subjects.  As  a  consequence,  a  careful  evaluation  of 
these specific abilities should become part  of periodic 
clinical evaluations of DMD children in preschool years 
and  prompt  rehabilitation  of  those  components  which 
could lead to deficiencies should be provided.
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Although the exact brain function is largely unknown, it 
is tempting to hypothesize a direct role of dystrophin (or 
its cerebral isoforms) in the cortical circuits involved in 
reading  as  seen  in  DD.  Analyses  of  larger  sample 
groups and further studies on functional neuroimaging 
(fMRI)  could  help  establish  possible  genotype 
correlations and more precisely verify learning deficits in 
DMD. This  information would  proved to be extremely 
useful in accurately evaluating preschool children before 
the overt  appearance of  muscular  manifestations  and 
promote a timely rehabilitation of weaker tasks.
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Conclusions and future directions
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Conclusions
The PhD work summarized in this thesis aimed at a full 
integration  of  clinical  competence  and  advanced 
diagnostic  procedures  that  are  needed  to  achieve  a 
correct diagnosis in neuromuscular disorders (NMD).
The  contribution  outlined  in  several  peer-reviewed 
articles and original data awaiting submission  further 
suggests  that  muscle  MRI  could  be  an  useful, 
non-invasive approach to select  the more appropriate 
genetic and biochemical investigations. Thus, it can be 
used as an additional tool in the diagnostic flow chart for 
the  improvement  of  the  differential  diagnosis.  Muscle 
MRI  analysis  also  plays  a  leading  role  on  the 
assignment of a pathogenic value to new mutations as 
well as on the recognition of muscular involvement in 
pre-symptomatic or not completely defined phenotype. 
Last but not least, it also offers useful information for a 
better understanding of the related pathogenesis.
With this final  aim and to go through its conventional 
use we have conducted a study focused on research of 
patterns not only related to a specific gene but different
pathogenetic  pathway.  In  fact,  we  have  looked  at 
markers capable to distinguish different forms in spite of 
an  apparently  similar  clinical  presentation.  This 
innovative  approach  brought  us  to  pinpoint  discrete 
alterations  of  the  inner  muscle  bulks  and  suggest
pathogenetic mechanisms in different forms of NMD. 
Additional  studies  will  be  necessary  to  validate  data 
presented in the present work, eventually with a higher 
“zooming”  on  muscle  structure  for  example  by  7T 
apparatus.
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Future directions
Most  of  the  published  studies  on  inherited  NMD 
employed  the  short  protocol  previously  described 
(Mercuri et al 2002). Although this has proved to be very 
effective for detecting patterns of muscle involvement in 
young patients, there are a number of other clinical and 
research issues that could be addressed with the use of 
a  extended  protocol  in  older  patients.  A  more 
comprehensive  protocol  (e.g.,  with  T2  and  STIR 
sequences) would not only provide valuable information 
on the possible presence of oedema (which may identify 
early  stages  of  muscular  involvement  as  shown  in 
Duchenne Muscular Dystrophy), but could also supply 
important clues as to the pathology of the muscles and 
the mechanisms of muscle damage. For example, STIR 
sequences may help to highlight pathology in muscles 
that  appear  normal  on  T1  images  by  removing  the 
signal  originating  from fat,  or  contribute  to  clarify  the 
nature  of  the  abnormal  signal  in  different  muscle 
disorders  due  to  different  gene  and  protein  defects, 
allowing for a pre-symptomatic diagnosis. 
The recently introduced advanced and quantitative MRI 
methods  including  T2  relaxation  time  measurements, 
muscle  fat  quantification  using  the  3-point  Dixon 
technique,  magnetic  resonance  spectroscopy,  and 
perfusion imaging are quite promising as well, but also 
represent  a future challenge in terms of  quantification 
and specification of the disease process and monitoring. 
Quantification  of  muscle  volume  by  muscle  MRI  and 
advanced quantitative MRI methods may be used for 
controlling  the  safety  and  efficacy  of  (experimental) 
treatment.  Its  application  in  a number  of  the  ongoing 
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therapeutic  trials,  where  cross-centre  comparability  of 
results is a prerequisite, has been greatly facilitated by 
the development of standard operating procedures for 
these  protocols  by  a  multinational,  multi-platform 
working group under  the auspices of  the international 
initiative TREAT-NMD. 
The limited number of sensitive outcome measures in 
this field and the need to avoid invasive techniques in a 
patient  population  where  muscle  function  is  already 
compromised makes MRI particularly  attractive in  this 
regard, and this is reflected in an increasing interest in 
quantitative MRI outcome measures from a regulatory 
and pharmaceutical industry perspective. 
Considering the paediatric population only, we have to 
exploit new diagnostic protocols associated with muscle 
MRI,  however,  in  order  to  make  the  examination 
suitable and not long-lasting.  
It could be of interest adopting a protocol of quantitative 
image  analysis  to  evaluate  muscle  fat  infiltration  for 
grading  different  forms  of  muscle  disorders,  and 
avoiding  needs  for  additional  sequences  that  expand 
time of analysis. 
Moreover  new  advanced  techniques  such  as 
ultra-high-field  MRI  (UHF-MRI),  with  their  greater 
signal-to-noise ratio  and spatial  resolution,  could offer 
increased image quality and promoting new and earlier 
information on muscle damage. 
Furthermore, the increased spectral resolution and the 
greater  sensitivity  to  low-gamma nuclei  available  with 
UHF-MRI should facilitiate use of  techniques such as 
1H  and  31P-MRS  improving  biochemical  and 
physiological imaging of skeletal muscle.  
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Two project exploiting the use of UHF-MRI have been 
designed and submitted to national funding agencies in 
order to understand its feasibility and its possible use in 
clinical  practice  with  the  final  aim  to  deepen  our 
knowledge of pathogenesis and potential targets.
In  particular,  we  have  defined  an  original  protocol  to 
integrate  data  from  ultra  high  deep-sequencing  (next 
generation  sequencing,  NGS)  technology  of  several 
cases presenting with limb-girdle muscle weakness and 
dystrophy and those emerging from UHF-MRI, followed 
by the dissection of the molecular pathways involved. 
NGS  currently  offers  new  opportunities  to  diagnose 
NMD,  confirm  the  pathogenetic  role  of  new  gene 
variants,  and evaluate better gene expression profiles 
and molecular interactions in primary muscle disorders. 
The  use  of  UHF-MRI   and  gene  expression  studies 
might  help  to  investigate  the  pathogenetic  pathways 
underlining muscle pathology and to address differential 
diagnosis. 
Moreover,  this  study  design  could  identify  novel 
molecular  pathways  and  new  potential  therapeutic 
targets.
Finally,  another  possible  future  application  of 
myoimaging  in  NMD  would  be  to  perform 
neurofunctional  MRI  acquisition  for  analyzing  and 
comparing  the  alteration  of  neurofunctional  circuit  in 
different diseases with brain involvement, as in DMD for 
example.  
Although  its  exact  function  in  the  brain  is  largely 
unknown, it is tempting to hypothesize a direct role of 
dystrophin  (or  its  cerebral  isoforms)  in  the  cortical 
circuits involved in reading as seen in dyslexic patients 
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in our own neuropshycological study. Analyses of larger 
sample  of  DMD  children  and  further  studies  on 
functional neuroimaging (fMRI) could help establishing 
possible  genotype-phenotype  correlations  and  more 
precisely  verify  learning  deficits  in  DMD.  This 
information has the lilihood to impact on evaluation of 
DMD  toddlers  in  preschool  years  before  the  overt 
appearance of muscular manifestations and promote a 
timely rehabilitation of weaker tasks.
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